IL151209A - Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation - Google Patents

Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation

Info

Publication number
IL151209A
IL151209A IL151209A IL15120902A IL151209A IL 151209 A IL151209 A IL 151209A IL 151209 A IL151209 A IL 151209A IL 15120902 A IL15120902 A IL 15120902A IL 151209 A IL151209 A IL 151209A
Authority
IL
Israel
Prior art keywords
radical
alkyl
radicals
alk
alkoxy
Prior art date
Application number
IL151209A
Other languages
Hebrew (he)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL151209A publication Critical patent/IL151209A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention concerns pharmaceutical compositions containing as active ingredient a compound of formula (I) wherein: R1 represents a -NHCOR4 or -N(R5)-Y-R6 radical; Y is CO or SO2; R4 represents an -alk-SO2R11, -alk-SO2-CH=CH-R11, Het substituted by -SO2R11 or phenyl substituted by -SO2-R11 or -alk-SO2-R11 radical; R5 represents a hydrogen atom or an alkyl radical; R6 represents a phenylalkyl radical, Het or Ar; the novel derivatives of formula (I) and their preparation.

Description

1 5077/02 151209/2 lD3Dm munn mun ,WOW\rm - 3 cu ππτ 3 a^ nn mnpn Ίτιιοτι PHARMACEUTICAL COMPOSITIONS CONTAINING 3-AMINOAZETIDINE DERIVATIVES, NOVEL DERIVATIVES AND THEIR PREPARATION The present invention relates to a compound formula : (I) in which • Ri represents a radical —NHCOR or —N(R5) —Y—R6; • Y is S02; • R2 and R3, which are identical or different, represent either an aromatic radical selected from phenyl, naphthyl and indenyl, these aromatics being unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoro-methoxy, --CO-alk, cyano, ~ COOH, --COOalk, ~CONR7 Rg, -CO--NH-- R9 Rio, alkylsulfanyl, alkylsulfmyl, alkyl-sulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or -alk- R7 Rg radicals; or a heteroaromatic radical selected from benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, pyrimidinyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, quinolyl, 1,2,3,4-tetrahydro-isoquinolyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic radicals to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, --COOH, --COOalk, —CO—NH--NR9 Rio, --CONR7 R8, -alk- NRg Rio, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, lkylsulfanylalkyl, alkylsulfinylalkyl, lkylsulfonylalkyl or hydroxyalkyl radical; R4 represents a phenyl substituted with —S02 —Rn; R5 represents a hydrogen atom or an alkyl radical; R6 represents a phenylalkyl, Het or Ar radical; R7 and R8, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R7 and Re together with the nitrogen atom to which they are attached form a 3- to 10- membered saturated mono- or bicyclic heterocycle, optionally further having another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals , Rg and Rio, which are identical or different, represent a hydrogen atom or an alkylf —COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or alternatively R9 and Rio together with the nitrogen atom to which they are attached form a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally further having another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, — COalk, --COOalk, —CO— Halk, —CS--NHalk, oxo, hydroxyalkyl, -alk-O-alk or —CO— H2 radicals, Rn represents an alkyl radical, Ar represents a phenyl, naphthyl or indenyl radical, these radicals being optionally substituted with one or more halogen atoms or alkyl, alkoxy, cyano, —COalk, --COOH, —COOalk, —CONRi2 Ri3, —CO—NH—NRi4 Ri5, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, - alk-NRi4 Ri5, —NRi Ri5, alkylthioalkyl, formyl, hydroxyl, hydroxyalkyl, —O-alk-NH-cycloalkyl, OCF3, CF3, ~NH~CO-alk, ~S02 NH2, — H—COCH3, — H— COOalk or Het radicals, or alternatively, a fused ring containing a 3-10 membered Het radical is formed on 2 adjacent carbon atoms of said Ar radical, with a dioxymethylene, said Het being an unsaturated or saturated mono- or bicyclic heterocycle having one or more heteroatoms selected from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, alkoxycarbonyl, oxo, hydroxyl, OCF3 or CF3 radicals, the heterocycles that have nitrogen being optionally in their N-oxidized form; • Ri2 and R13, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively Ri2 and R13 together with the nitrogen atom to which they are attached form a 3- to 10- membered saturated mono- or bicyclic heterocycle, optionally further having another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals ; • Ri4 and R15, which are identical or different, represent a hydrogen atom or an alkyl, —COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or alternatively R14 and R15 together with the nitrogen atom to which they are attached form a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally further having another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, — COalk, --COOalk, --CO— Halk, --CS--NHalk, oxo, hydroxyalkyl, -alk-O-alk or —CO—NH2 radicals, • alk represents an alkyl or alkylene radical, • the alkyl and alkylene radicals and portions and the alkoxy radicals and portions are in the form of a straight or branched chain having 1 to 6 carbon atoms and the cycloalkyl radicals have 3 to 10 carbon atoms, or the optical isomers thereof or pharmaceutically acceptable salts of such compound, with the exception of any compound in which R2 and R3 represent phenyl radicals, Ri represents a radical — (R5)—Y—R6, Y is S02, 5 represents a methyl radical and R6 represents a phenyl radical .
The present invention relates also to a process for preparing a compound of formula (I) as described above in which Ri represents a radical — HCOR4, the process comprising reacting an acid R4 COOH for which R4 has the same meanings as described above with a derivative of formula: in which R2 and R3 have the same meanings as described above, isolating the product, and optionally converting the product to a pharmaceutically acceptable salt.
The present invention further relates to a pharmaceutical composition comprising, as an active ingredient, a compound of formula: in which • Ri represents a radical — HCOR4 or — (R5) —Y—R6, • Y is CO or S02, • R2 and R3, which are identical or different, represent either an aromatic radical selected from phenyl, naphthyl and indenyl, these aromatic radicals being unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoro-methoxy, —CO- alk, cyano, —COOH, --COOalk, —CON 7 Re, —CO—NH— NRg Rio, alkylsulfanyl, alkylsulfinyl, alkyl- sulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or -alk-NR7 R8 radicals; or a heteroaromatic radical selected from benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2, 3-dihydrobenzofuryl, 2,3- dihydrobenzothienyl, pyrimidinyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, quinolyl, 1, 2, 3, 4-tetrahydroisoquinolyl, thiazolyl and thienyl rings, these heteroaromatic radicals being unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, —COOH, —COOalk, —CO— H- e -NRg Rio, —CONR7 R8, -alk-NRg Rio, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl radical, R4 represents a phenyl substituted with —S02 —Rn, R5 represents a hydrogen atom or an alkyl radical, R6 represents a phenylalkyl, Het or Ar radical, R7 and R8, which are identical or different, represent a hydrogen atom or an alkyl radical or, alternatively, R7 and R8 form, together with the nitrogen atom to which they are attached, a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, R9 and Rio, which are identical or different, represent a hydrogen atom or an alkyl, —COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or, alternatively, Rg and Rio form, together with the nitrogen atom to which they are attached, a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, said heterocycle optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, — COalk, --COOalk, --CO~NHalk, --CS--NHalk, oxo, hydroxyalkyl, -alk-O-alk or —CO— H2 radicals, Rn represents an alkyl radical, Ar represents a phenyl, naphthyl or indenyl radical, these radicals being optionally substituted with one or more halogen atoms or alkyl, alkoxy, cyano, —COalk, --COOH, —COOalk, --CONR12 R13, --CO--NH—NR14 Ri5, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, - alk-NRi4 Ri5, — Ri4 Ri5, alkylthioalkyl , formyl, hydroxyl, hydroxyalkyl, --O-alk-NH-cycloalkyl, OCF3, CF3, —NH—CO-alk, --SO2 NH2, —NH--COCH3, — H— COOalk or Het radicals or, alternatively, a fused ring containing a 3-10 membered Het radical is formed on 2 adjacent carbon atoms of said Ar radical, with a dioxymethylene, said Het being an unsaturated or saturated mono- or bicyclic heterocycle containing one or more heteroatoms selected from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, alkoxycarbonyl, oxo, hydroxyl, OCF3 or CF3 radicals, the nitrogen-containing heterocycles being optionally in their N-oxidized form, R12 and Ri3, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R12 and R13 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ri4 and R15, which are identical or different, represent a hydrogen atom or an alkyl, --COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or alternatively Ri4 and R15 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, — COalk, —COOalk, —CO— Halk, —CS--NHalk, oxo, hydroxyalkyl, -alk-O-alk or —CO— H2 radicals, • alk represents an alkyl or alkylene radical, • the alkyl and alkylene radicals and portions and the alkoxy radicals and portions are in the form of a straight or branched chain and contain 1 to 6 carbon atoms and the cycloalkyl radicals contain 3 to 10 carbon atoms, an optical isomer of such a compound or one of its pharmaceutically acceptable salts. 151209/1 lh The present invention relates to pharmaceutical compositions containing, as active ingredient, at least one compound of formula: or one of its pharmaceutically acceptable salts, to the novel derivatives of formula (I), to their pharmaceutically acceptable salts and to their preparation.
The compound of formula (I) for which R2 and R3 represent phenyl radicals, Rx represents a radical -N(Rs)-Y-R6, Y is S02, Rs represents a methyl radical and R6 represents a phenyl radical is described as a synthesis intermediate in Patent WO 99/01451. The other compounds and their pharmaceutically acceptable salts are novel and as such form parts of the invention.
In formula (I) Ri represents a radical -NHCOR4 or -N(R5)-Y-R6, Y is CO or S02, 2 R2 and R3, which are identical or different, represent either an aromatic chosen from phenyl, naphthyl and indenyl, these aromatics being unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl , trifluoro-methoxy, -CO-alk, cyano, -COOH, -COOalk, -CONR7R8, -CO-NH-NR9R10, alkylsulfanyl, alkylsulfinyl , alkyl-sulfonyl, alkylsulfanylalkyl , alkylsulfinylalkyl , alkylsulfonylalkyl , hydroxyalkyl or -alk-NR7R8 radicals; or a heteroaromatic chosen from benzofuryl, benzothiazolyl , benzothienyl , benzoxazolyl , chromanyl, 2, 3-dihydrobenzofuryl, 2, 3-dihydrobenzothienyl , pyrimidinyl, furyl, imidazolyl, isochromanyl , isoquinolyl, pyrrolyl, pyridyl, quinolyl , 1 , 2 , 3 , 4 -tetrahydro-isoquinolyl , thiazolyl and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl , trifluoromethoxy, cyano, -COOH, -COOalk, -C0-NH-NR9R10, -CONR7R8, -alk-NRgRio, alkylsulfanyl , alkylsulfinyl , alkylsulfonyl , alkylsulfanylalkyl , alkylsulfinylalkyl , alkylsulfonylalkyl or hydroxyalkyl radical, R4 represents a radical -alk-S02-Rn, -alk-S02-CH=CH-Ru , Het substituted with -S02-Rn or phenyl substituted with -SO2-R11 or -alk-S02-Rn, R5 represents a hydrogen atom or an alkyl radical, R6 represents a phenylalkyl, Het or Ar radical, 151209/2 R7 and Re, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R7 and Re together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono-or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Rg and Rio, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or alternatively Rg and Rio together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl,. -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or -CO-NH2 radicals, R11 represents an alkyl, Ar or Het radical, Ar represents a phenyl, naphthyl or indenyl radical, these radicals being optionally substituted with one or more halogen atoms or alkyl, alkoxy, cyano, -CO-alk, -COOH, -COOalk, -CONR12R13, -CO-NH-NR14R15, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -alk-NR^Ris, -NR1 R15, alkylthioalkyl, formyl, hydroxyl, hydroxyalkyl, -O-alk-NH-cycloalkyl, OCF3, CF3, -NH-CO-alk, -S02NH2, 4 -NH-COCH3, -NH-COOalk or Het radicals, or alternatively, on 2 adjacent carbon atoms, with a dioxymethylene , Het represents a 3- to 10-membered unsaturated or saturated mono- or bicyclic heterocycle containing one or more heteroatoms chosen from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, alkoxycarbonyl , oxo, hydroxyl, OCF3 or CF3 radicals, the nitrogen-containing heterocycles being optionally in their N-oxidized form, Ri2 and R13, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively Ri2 and Ri3 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono-or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals , Ri4 and R15, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl, alkylcycloalkyl , -alk-O-alk or hydroxyalkyl radical or alternatively R1 and R15 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl , -alk-O-alk or -CO-NH2 radicals, alk represents an alkyl or alkylene radical.
In the preceding definitions and in those which follow, unless otherwise stated, the alkyl and alkylene radicals and portions and the alkoxy radicals and portions are in the form of a straight or branched chain and contain 1 to 6 carbon atoms and the cycloalkyl radicals contain 3 to 10 carbon atoms.
Among the alkyl radicals, there may be mentioned the methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl and hexyl radicals. Among the alkoxy radicals, there may be mentioned the methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and pentyloxy radicals.
Among the cycloalkyl radicals, there may be mentioned the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals.
The term halogen comprises chlorine, fluorine, bromine and iodine. J Among the heterocycles represented by Het, the following heterocycles may be mentioned: benzimidazole, benzoxazole, benzothiazole, benzothiophene , cinnoline, thiophene, quinazoline , . quinoxaline, quinoline, pyrazole, pyrrole, pyridine, imidazole, indole, isoquinoline , pyrimidine, thiazole, thiadiazole, piperidine, piperazine, pyrrolidine, 6 triazole, furan, tetrahydroisoquinoline, tetrahydroquinoline , these heterocycles being optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, alkoxycarbonyl , oxo, hydroxyl, OCF3 or CF3 radicals.
The compounds of formula (I) may be provided in the form of enantiomers and of diastereoisomers . These optical isomers and mixtures thereof also form part of the invention.
Preferably, the compounds of formula (I) are those for which Ri represents a radical -N(R5)-Y-R6, Y is S02, R2 represents either a phenyl which is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, trifluoromethyl , trifluoromethoxy , cyano, -CONR7R8, hydroxyalkyl or -alk-NRvRg radicals; or a heteroaromatic chosen from the pyridyl, pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl , trifluoromethoxy, -CONR7R8, -alk-NRgRio, alkylsulfanyl , alkylsulfinyl , alkylsulfonyl or hydroxyalkyl radical, R3 represents either a phenyl which is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, trifluoromethyl , trifluoromethoxy , cyano, -CONR7Ra, hydroxyalkyl or -alk-NR7Rs radicals; or a 7 heteroaromatic chosen from the pyridyl, pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, -CONR7R8, -alk-NRgRio/ alkylsulfanyl , alkylsulfinyl , alkylsulfonyl or hydroxyalkyl radical, R5 represents a hydrogen atom or an alkyl radical, R6 represents a naphthyl, phenylalkyl, Het or phenyl radical' optionally substituted with one or more halogen atoms or alkyl, alkoxy, cyano, -CO-alk, COOalk, -CONR12Ri3, -alk- RnRis, -NR14R15, hydroxyl, hydroxyalkyl, Het, OCF3, CF3, -NH-CO-alk, -S02NH2 or -NH-COOalk radicals,' or alternatively, on 2 adjacent carbon atoms, with dioxymethylene , R7 and Re, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R7 and R$ together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono-or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, R9 and Rio, which are identical or different, represent a hydrogen atom or an alkyl, cycloalkyl, alkylcycloalkyl or hydroxyalkyl radical or alternatively Rg and Rio together form with the nitrogen atom to which they are attached a 3- to 10-membered 8 saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, oxo or -CO-NH2 radicals, R12 and R13, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R12 and Ri3 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals , Ri4 and R15, which are identical or different, represent a hydrogen atom or an alkyl, cycloalkyl, alkylcycloalkyl or hydroxyalkyl radical or alternatively Ri4 and R15 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, · optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, oxo, hydroxyalkyl or -CO-NH2 radicals, Het represents a 3- to 10-membered unsaturated or saturated mono- or bicyclic heterocycle containing one or more heteroatoms chosen from oxygen, sulfur and " nitrogen optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, alkoxycarbonyl , 9 oxo or hydroxyl radicals, the nitrogen-containing heterocycles being optionally in their N-oxidized form and, preferably, Het represents a heterocycle chosen from the following heterocycles: benzimidazole , benzoxazole, benzothiazole, benzothiophene , thiophene, quinazoline, quinoxaline, quinoline, pyrrole, pyridine, imidazole, indole, isoquinoline , pyrimidine, thiazole, thiadiazole, furan, tetrahydroisoquinoline and tetrahydroquinoline, these heterocycles being optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, οχσ, hydroxyl, OCF3 or CF3 radicals .
Still more preferably, the compounds of formula (I) are chosen from the following compounds: Ri represents a radical -N(R5)-Y-R6, Y is S02, R2 represents either a phenyl which is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, trifluoromethyl, trifluoromethoxy or hydroxyalkyl radicals; or a heteroaromatic chosen from pyridyl and pyrimidyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl or trifluoromethoxy radical, R3 represents either a phenyl which is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, trifluoromethyl , trifluoromethoxy or hydroxyalkyl radicals; or a heteroaromatic chosen from pyridyl and pyrimidyl rings, it being possible for these heteroaromatics to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl or trifluoromethoxy radical, R5 represents a hydrogen atom or an alkyl radical, Re represents a naphthyl, phenylalkyl, Het or phenyl radical optionally substituted with one or more halogen atoms or alkyl, alkoxy, -NR14R15, hydroxyl, hydroxyalkyl , OCF3, CF3 or -SO2NH2 radicals, or alternatively, on 2 adjacent carbon atoms, with dioxymethylene , Ri4 and R15, which are identical or different, represent a hydrogen atom or an alkyl, cycloalkyl, alkylcycloalkyl or hydroxyalkyl radical or alternatively R14 and R15 together, form with the nitrogen atom to which they are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom chosen from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, oxo, hydroxyalkyl or -CO-NH2 radicals, Het represents a 3- to 10-membered unsaturated ■ or saturated mono- or bicyclic heterocycle containing one or more heteroatoms chosen from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, alkoxycarbonyl , oxo or hydroxyl radicals, the nitrogen-containing heterocycles being optionally in their N-oxidized form and, preferably, Het represents a heterocycle chosen 11 from the following heterocycles : benzimidazoie , benzoxazole, benzothiazole , benzothiophene , thiophene, quinoline, pyrrole, pyridine, pyrimidine, thiazole, thiadiazole, furan, tetrahydroisoquinoline and tetrahydroquinoline, these heterocycles being optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, oxo, hydroxyl, OCF3 or CF3 radicals.
The compounds of formula (I) for which Rx represents a radical -NHCOR4 may be prepared according to the following reaction scheme: In these formulae, R2, R3 and R4 have the same meanings as in formula (I).
Step a is generally carried out in an inert solvent such as tetrahydrofu'ran, dioxane, a chlorinated solvent (for example dichloromethane or chloroform), at a temperature of between 15 and 30°C, in the presence of a base such as a trialkylamine (for example 12 triethylamine or dipropylethylamine ) or in pyridine, at a temperature of between 0 and 30°C.
Step b is preferably carried out in methanol, in an autoclave, at a temperature of between .50 and 70°C.
Step c is generally carried out in the presence of a condensing agent used in peptide chemistry, such as a carbodiimide (for example 1- ( 3-dimethylamiopropyl ) -3-ethylcarbodiimide or N, N' -dicyclohexylcarbodiimide) or N, ' carbonyl-diimidazole, in an inert solvent such as an ether (for example tetrahydrofuran or dioxane) , an amide (dimethylformamide) or a chlorinated solvent (for example methylene . chloride, 1 , 2-dichloroethane or chloroform) at a temperature of between 0°C and the boiling point of the reaction mixture. It is also possible to use a reactive derivative of the acid such as an acid chloride, optionally in the presence of an acid acceptor such as a nitrogen-containing organic base (for example trialkylamine , pyridine, 1,8-diaza-bicyclo [ 5.4.0 ] undec-7-ene or 1 , 5-diazabicyclo [ 4.3.0] -non-5-ene) , in a solvent as cited above, or a mixture of these solvents, at a temperature of between 0°C and the boiling point of the reaction mixture.
The derivatives R4COOH are commercially available or may be obtained according to the methods described in R.C.. LAROCK, Comprehensive Organic Transformations, VCH editor. 13 The azetidinols of formula 1 may be obtained by application or adaptation of the methods described by KATRITZKY A.R. et al . , J. Heterocycl . Chem. , 271 (1994) or DAVE P.R., J. Org. Chem., 61, 5453 (1996) and in the examples. The procedure is generally carried out according to the following reaction scheme: in these formulae, R2 and R3 have the same meanings as in formula (I) and Hal represents a chlorine or bromine atom.
In step A, the procedure is preferably carried out in an inert solvent such as a 1-4C aliphatic alcohol (for example ethanol or methanol), optionally in the presence of an alkali metal hydroxide, at the boiling point of the reaction medium. 14 In step B, the reduction is generally carried out by means of lithium aluminum hydride, in tetrahydrofuran at the boiling point of the reaction medium.
In step C, the procedure is preferably carried out in an inert solvent such as a 1-4C aliphatic alcohol (for example ethanol or - methanol ) , in the presence of sodium hydrogen carbonate, at a temperature of between 20°C and the boiling point of the reaction medium.
In step D, the procedure is carried out according to the method described by GRISAR M. et al . in J. Med. Chem., 885 (1973) . The magnesium compound of the brominated derivative is formed and then the nitrile is caused to react, in an ether such as ethyl ether, at a temperature of between 0°C and the boiling point of the reaction medium. After hydrolysis with an alcohol, the intermediate imine is reduced in situ with sodium borohydride at a temperature of between 0°C and the boiling point of the reaction medium.
The derivatives R2-CO-R3 are commercially available or may be obtained by application or adaptation of the methods described by KUNDER N.G. et al. J. Chem. Soc. Perkin Trans 1, 2815 (1997); MORENO-MARRAS M . , Eur. J. Med. Chem., 23 (5) 477 (1988); SKINNER et al . , J. Med. Chem., l± (6) 546 (1971); HURN N.K., Tet. Lett., 36 (52) 9453 (1995); MEDICI A. et al., Tet. Lett., 24 (28) 2901 (1983); RIECKE R.D. et al., J. Org. Chem. , 62 (20) 6921 (1997); KNABE J. et al., Arch. Pharm. , 306 (9) 648 (1973); CONSONNI R. et al., J. Chem. Soc. Perkin Trans 1, 1809 (1996); FR-96-2481 and JP-94-261393.
The derivatives R3Br are commercially available or may be obtained by application or adaptation of the methods described by BRANDSMA L. et al., Synth. Comm., 20 (11) 1697 and 3153 (1990); LEMAIRE M . et al . , Synth. Comm., 24_ (1) 95 (1994); GODA H. et al . , Synthesis, 9 849 (1992); BAEUERLE P. et al., J. Chem. Soc. Perkin Trans 2, 489 (1993) .
The derivatives R2CN are commercially available or may be obtained by application or adaptation of the methods described by BOUYSSOU P. et al., J. Het. Chem., 29 (4) 895 (1992); SUZUKI N. et al., J. Chem. Soc. Chem. Comm., 1523 (1984); MARBURG S. et al., J. Het. Chem.., 17 1333 (1980); PERCEC V. et al., J. Org. Chem., 60 (21) 6895 (1995) .
The compounds of formula (I) for which Ri represents a radical -N(R5)-Y-R6 may be prepared according to the following reaction scheme: 16 in these formulae, Y, R2, R3 and Rg have the same meanings as in formula (I), Hal represents a halogen atom and, preferably, an iodine, chlorine or bromine atom.
Step a is generally carried out in an inert solvent such as tetrahydrofuran, dioxane or a chlorinated solvent (for example dichloromethane or chloroform) , in the presence of an amine such as a trialkylamine (for example triethylamine ) , at a temperature of between 5°C and 20°C.
Step b is generally carried out in an inert solvent such as tetrahydrofuran, in the presence of sodium hydride, at a temperature of 0°C and the boiling point of the reaction medium.
The Hal-S02R6 derivatives are commercially available or may be obtained by halogenation of the corresponding sulfonic acids, in particular in situ in the presence of chlorosulfonyl isocyanate and alcohol, in a halogenated solvent (for example dichloromethane or chloroform) .
The Hal-CO-Rg derivatives are commercially-available or may be prepared according to the methods described in R. C. LAROCK, Comprehensive Organic Transformations, VCH editor.
The compounds of formula (I) may also be prepared according to the following reaction scheme: In these formulae, Rj., R2 and R3 have the same meanings as in formula (I) and Ph represents a phenyl.
Step a is generally carried out in an alcohol such as methanol, in the presence of sodium borohydride, at a temperature in the region of 20°C. 18 In step b, the magnesium compound of the brominated derivative is prepared and it is caused to react, in an inert solvent such as ethyl ether or tetrahydrofuran, at a temperature of between 0°C and the boiling point of the reaction medium.
Step c is carried out by means of a halogenating agent such as hydrobromic acid, thionyl bromide, thionyl chloride, a mixture of triphenylphosphine and carbon tetrabromide or tetrachloride, in acetic acid or an inert solvent such as dichloromethane , . chloroform, carbon tetrachloride or toluene, at a temperature of between 0°C and the boiling point of the reaction medium.
Step d is carried out by means of hydrogen, in the presence of palladized charcoal, in an alcohol such as methanol, at a temperature in the region of 20°C.
Step e is carried out in an inert solvent such as acetonitrile , in the presence of an alkali. metal carbonate (for example potassium carbonate) and potassium iodide, at a temperature of between 20°C and the boiling point of the reaction medium.
The derivatives R3Br and the derivatives R2- CHO are commercially available or may be obtained according to the methods described for example by R.C. LAROCK, Comprehensive Organic Transformations, VCH editor . 19 The compounds of formula (I) for which Ri represents a 'radical -N(R5)-Y-Re in which Rs is a phenyl radical substituted with a hydroxyl radical may also be prepared by hydrolysis of a corresponding compound of formula (I) for which Rx represents a radical -N(R5)-Y-Re in which R6 is a phenyl radical substituted with an alkoxy radical.
This hydrolysis is generally carried out in an inert solvent such as a chlorinated solvent (for example dichloromethane or chloroform) , by means of boron tribromide, at a temperature in the region of 20°C.
The compounds of formula (I) for which Ri represents a radical -N(R5)-Y-R6 in which R6 is a phenyl radical substituted with a hydroxy ( 1C) alkyl radical may also be prepared by the action of diisobutylaluminum hydride on a corresponding compound of formula (I) for which Ri represents a radical -N(Rs)-Y-R6 in which R6 is a phenyl radical substituted with an alkoxycarbonyl radical.
This reaction is generally carried out in an inert solvent such as toluene, by means of diisopropyl-aluminum hydride, at a temperature of between -50°C and 25°C.
The compounds of formula (I) for which Ri represents a radical -N(R5)-Y-R6 in which R6 is a phenyl radical substituted with a 1-pyrrolidinyl radical may also be prepared by the action of pyrrolidine and of a corresponding compound of formula (I) for which Ri represents a radical -N(R5)-Y-R6 in which R6 is a phenyl radical substituted with a fluorine atom.
This reaction is preferably carried out in an inert solvent such as dimethyl sulfoxide, at a temperature of 90°C.
It is understood for persons skilled in the art that, to carry out the processes according to the invention which are described above, it may be necessary to introduce groups protecting amino, hydroxyl and carboxyl functions in order to avoid side reactions. These groups are those which allow removal without affecting the rest of the molecule. As examples of groups protecting the amino function, there may be mentioned tert-butyl or methyl carbamates which may be regenerated using iodotrimethylsilane or allyl using palladium catalysts. As examples of groups protecting the hydroxyl function, there may be mentioned triethylsilyl and tert-butyldimethylsilyl which may be regenerated using tetrabutylammonium fluoride or alternatively asymmetric acetals (methoxymethyl or tetrahydropyranyl for example) with regeneration using hydrochloric acid. As groups protecting carboxyl functions, there may be mentioned esters (allyl or benzyl for example), oxazoles and 2-alkyl-l , 3-oxazolines. Other protecting groups which can be used are described by GREENE T.W. et al . , Protecting Groups 21 in Organic Synthesis, second edition, 1991, John Wiley & Sons .
The compounds of formula (I) may be purified by the customary known methods, for example by crystallization, chromatography or extraction.
The enantiomers of the compounds of formula (I) may be obtained by resolution of the racemates for example by chromatography on a chiral column according to PIRCKLE W.H. et al . , Asymmetric synthesis, Vol. 1, Academic Press (1983) or by formation of salts or by synthesis from chiral · precursors . The diastereoisomers may be prepared according to known conventional methods (crystallization, chromatography or from chiral precursors) .
The compounds of formula (I) may be optionally converted to addition salts- with an inorganic or organic acid by the action of such an acid in an organic solvent such as an alcohol, a ketone, an ether or a chlorinated solvent. These salts also form part of the invention.
As examples of pharmaceutically acceptable salts, the following salts may be mentioned: benzenesulfonate , hydrobromide , hydrochloride, citrate, ethanesulfonate, fumarate, gluconate, iodate, isethionate, maleate, methanesulfonate , methylene-bis-β-oxynaphthoate , nitrate, oxalate, pamoate, phosphate, salicylate, succinate, sulfate, tartrate, theophyllineacetate and p-toluenesulfonate . 22 The compounds of formula (I) exhibit advantageous pharmacological properties. These compounds possess a high affinity for the cannabinoid receptors and particularly those of the CB1 type. They are CBl-receptor antagonists and are therefore useful in the treatment and prevention of disorders affecting the central nervous system, the immune system, the cardiovascular or endocrine system, the respiratory system, the gastrointestinal apparatus and reproductive disorders (Hollister, Pharm. Rev.; 38, 1986, 1-20, Reny and Sinha, Prog. Drug Res., 36, 71-114 (1991), Consroe and Sandyk, in Marij uana/Cannabinoids , Neurobiology and Neurophysiology, 459, Murphy L. and Barthe A. Eds, CRC Press, 1992) .
Accordingly, these compounds may be used for the treatment or prevention of psychoses including schizophrenia, anxiety disorders, depression, epilepsy, neurodegeneration, cerebellar and spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheral neuropathies, glaucomas, migraine, Parkinson's disease, Alzheimer's disease, Huntington's chorea, Raynaud's syndrome, tremor, obsessive-compulsive disorder, senile dementia, thymic disorders, Tourette ' s .syndrome, tardive dyskinesia, bipolar disorders, cancers, movement disorders induced by medicaments, dystonia, endotoxemic shocks, hemorrhagic shocks, hypotension, insomnia, immunological diseases, multiple sclerosis, vomiting, asthma, appetite 23 disorders (bulimia, anorexia) , obesity, memory disorders, in weaning from chronic treatments and alcohol or drug abuse (opioids, barbiturates, cannabis, cocaine, amphetamine, phencyclide, hallucinogens, benzodiazepines for example) , as analgesics or potentiators of the analgesic activity of the narcotic and nonnarcotic drugs. They may also be used for the treatment or prevention of intestinal transit.
The affinity of the compounds of formula (I) for the cannabis receptors has been determined according to the method described by KUSTER J.E., STEVENSON J.I., WARD S.J., D'AMBRA T.E., HAYCOCK D.A. in" J. Pharmacol. Exp. Ther., 264 1352-1363 (1993) .
In this test, the IC50 of the compounds of formula (I) is less than or equal to 1000 nM .
Their antagonist activity has been shown by means of the model of hypothermia induced by an agonist of the- cannabis receptors (CP-55940) in mice, according to the method described by Pertwee R.G. in Marijuana, Harvey D.J. eds, 84 Oxford IRL Press, 263-277 (1985) .
In this test, the ED50 of the compounds of formula (I) is less than or equal to 50 mg/kg.
The compounds of formula (I) exhibit low toxicity. Their LD50 is greater than 40 mg/kg by the subcutaneous route in mice.
The following examples illustrate the invention . 24 Example 1 69.3 mm3 of triethylamine and 110 mg of thien-2-ylsulfonyl chloride are successively added, at room- temperature and under an argon atmosphere, to a solution of 61.4 mg of 1- [bis ( 4 -chlorophehyl ) methyl] -azetidin-3-ylamine in 3 cm3 of dichloromethane . After stirring for 68 hours at room temperature, the reaction mixture is introduced into a Bond Elut® SCX cartridge (3 cm5/500 mg) , eluting successively with twice 2 cm3 of dichloromethane and then twice 2 cm3 of a 1 M solution · of ammonia in methanol. The ammoniacal fractions are pooled and concentrated to dryness under reduced pressure (2.7 kPa) . The residue obtained is dissolved in 5 cm3 of dichloromethane, washed with three times 3 cm3 of distilled water, dried over magnesium sulfate, filtered and concentrated to. dryness under reduced pressure (2.7 kPa) . 60 mg of N- { 1- [bis ( 4 -chlorophenyl ) -methyl ] azetidin-3-yl } thien-2-ylsulfonamide are thus obtained in the form of. a cream-colored foam [1H NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.77 (split t, J = 7 and 2 Hz : 2H) ; 3.'40 (split t, J = 7 and 2 Hz : 2H) ; 4.06 (mt : 1H) ; 4.21 (s : 1H) ; from 4.85 to 5.25 (broad unresolved complex : 1H) ; 7.06 (t , J = 4.5 Hz : 1H) ; from 7.15 to 7.35 (mt : 8H) ; 7.58 (mt : 2H) ] .. 1- [Bis (4-chlorophenyl)methyl] azetidin-3-yl-amine may be obtained in the following manner: 400 cm3 of a mixture of methanol and liquid ammonia (50/50 by volume) are added to 27 g of 1- [bis ( 4 -chlorophenyl ) - methyl] azetidin-3-yl methylsulfonate contained in an autoclave previously cooled to around -60°C. The reaction medium is then stirred at 60°C for 24 hours and then abandoned in the open air to allow the evaporation of the ammonia and finally concentrated under reduced pressure (2.7 kPa) . The residue is taken up in 500 cm3 of a 0.37 N aqueous sodium hydroxide solution and extracted with four times 500 cm3 of ethyl ether. The combined organic phases are washed successively with twice 100 cm3 of .distilled water and 100 cm3 of a saturated sodium chloride solution, dried over magnesium sulfate, filtered and concentrated under reduced pressure (2.7 kPa) . The residue obtained is purified by flash chromatography on silica gel [eluant: dichloromethane/methanol (95/5 by volume)] . 14.2 g of 1- [bis ( 4 -chlorophenyl ) methyl ] azetidin-3-ylamine are obtained in the form of an oil which solidifies into a cream-colored solid. 1- [Bis ( 4 -chlorophenyl) methyl] azetidin-3-yl methylsulfonate may be prepared in the following manner: 3.5 cm3 of methylsulfonyl chloride are added, under argon over 10 minutes, to a solution of 12 g of 1- [bis ( 4-chlorophenyl) methyl] azetidin-3-ol in 200 cm3 of dichloromethane and then the mixture is cooled to +5°C and 3.8 cm3 of pyridine are poured in over 10 minutes. After stirring for 30 minutes at +5°C and then for 20 hours at 20°C, the reaction mixture is diluted with 100 cm3 of water and 100 cm3 of dichloromethane. The 26 mixture, which is first filtered, is separated after settling. The organic phase is washed with water and then dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) . The oil obtained is chromatographed on a silica gel column (particle size 0.063-0.200 mm, height 40 cm, diameter 3.0 cm), eluting under an argon 'pressure of 0.5 bar with a mixture of cyclohexane and ethyl acetate (70/30 by volume) and collecting 100-cm3 fractions. Fractions 4 to 15 are combined and concentrated to dryness under reduced pressure (2.7 kPa) . 6.8 g of 1- [bis ( 4 -chlorophenyl ) methyl ] - azetidin-3-yl ester of methylsulfonic acid are obtained in the form of a yellow oil. 1- [Bis (4-chlorophenyl)methyl] azetidin-3-ol may be prepared according to the procedure described by KATRITZKY A.R. et al . , J. Heterocycl. Chem. , 271 (1994), starting with 35.5 g of [bis(4- chlorophenyl ) methyl ] -amine hydrochloride and 11.0 cm3 of epichlorohydrin . 9.0 g of l-[bis(4- chlorophenyl) methyl] azetidin-3-ol are isolated.
[Bis ( 4 -chlorophenyl ) methyl ] amine hydrochloride may be prepared according to the method described by GRISAR M. et al . , J. Med. Chem., 885 (1973) .
Example 2 By carrying out the operation according to the procedure of Example 1, but starting with 124 mg of 27 4 -methoxyphenylsulfonyl chloride, 12 mg of N-{l-[bis (4-chlorophenyl) methyl]azetidin-3-yl}-4 -methoxyphenylsulfonamide are obtained in the form of a cream-colored lacquer [l NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.70 (split t, J = 7 and 2 Hz : 2H) ; 3.35 (split t, J = 7 and 2 Hz : 2H) ; 3.85 (s : 3H) ; 3.94 (mt : 1H) ; 4.18 (s : 1H) ; 4.83 (d, J = 9 Hz : 1H) ; 6.94 (broad d, J = 9 Hz : 2H) ; 7.22 (s : 8H) ; 7.75 (broad d, J = 9. Hz : 2H) ] .
Example 3 By carrying out the operation according to the procedure of Example 1, but starting with 140 mg of 4 -acetamidophenylsulfonyl chloride, 13 mg of N-[4-(N-{l-[bis ( 4-chlorophenyl) methyl] azetidin-3-yl } sulfamoyl) phenyl] acetamide are obtained in the form of a cream-colored lacquer [ 1H NMR spectrum (300 MHz , CDCI3, δ in ppm): 2.26 (s : 3H) ; 2.74 (split t> J = 7 and 2 Hz : 2H) ; 3.39 (split t , J = 7 and 2 Hz : 2H); 4.01 (mt : 1H) ; 4.22 (s : 1H) ; 4.92 (d, J = 9 Hz : 1H) ; 7.32 (mt : 8H) ; 7.49 (broad s : 1H) ; 7.68 (broad d, J = 9 Hz : 2H) ; 7.81 (broad d, J = 9 Hz : 2H) ] .
Example 4 By carrying out the operation according to the procedure of Example 1, but starting with 114' mg of 4-methylphenylsulfonyl chloride, 19 mg of N-(l-[bis- ( 4-chlorophenyl) methyl] azetidin-3-yl } -4-methylphenyl-sulfonamide are obtained in the form of a colorless 28 lacquer [XH NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.42 (s : 3H) ; 2.71 (split t, J = 7 and 2 Hz : 2H) ; 3.36 (split t, J = 7 and 2 Hz : 2H) ; 3.97 (mt : 1H) ; 4.19 (s : 1H) ; 4.81 (d, J = 9.5 Hz : 1H) ; from 7.15 to 7.40 (mt : 10H) ; 7.71 (broad d, J = 8.5 Hz : 2H) ] .
Example 5 By carrying out the operation according to the procedure of Example 1, but starting with 142 mg of 3 , 4-dimethoxyphenylsulfonyl chloride, 10 mg of N- { 1- [b s (4-chlorophenyl) methyl] azetidin-3-yl } - 3 , 4-dimethoxyphenylsulfonamide are obtained in the form of a cream-colored lacquer [1H NMR spectrum (300 MHz, CDCI3, δ in ppm) : 2.72 (broad t, J = 7.5 Hz : 2H) ; 3.37 (broad t, J = 7.5 Hz : 2H) ; from 3.-85 to 4.00 (mt : 1H) ; 3.91 (s : 3H) ; 3.93 (s : 3H) ; 4.19 (s : 1H) ; 4.84 (d, J = 9 Hz : 1H) ; 6.90 (d, J = 8.5 Hz : 1H) ; 7.23 (mt : 8H) ; 7.29 (d, J = 2 Hz : 1H) ; 7.43 (dd, J = 8.5 and 2 Hz : 1H) ] .
Example 6 By carrying out the operation according to the procedure of Example 1, but starting with 117 mg of 3-fluorophenylsulfonyl chloride, 13.5 mg of N- { 1- [bis (4-chlorophenyl) methyl] azetidin-3-yl } -3-fluorophenyl-sulfonamide are obtained in the form of a cream-colored lacquer [ΧΗ NMR spectrum (400 MHz, CDC13, δ in ppm) : 2.79 (split t, J = 7 and 2 Hz : 2H) ; 3.43 (split t, J = 7 and 2 Hz : 2H) ; 4.05 (unresolved complex : 1H) ; 4.24 (s : 1H) ; 4.91 (unresolved complex 29 : 1H) ; from 7.20 to 7.40 (mt : 9H) ; from 7.50 to 7.65 (mt : 2H) ; 7.67 (broad d, J = 8 Hz : 1H) ] .
Example 7 By carrying out the operation according to the procedure of Example 1, but starting with 147 mg of 3 , 4 -dichlorophenylsulfonyl chloride, 20 mg of N- { 1- [bis (4-chlorophenyl ) methyl ]azetidin-3-yl}-3, 4-dichlorophenylsulfonamide are obtained in the form of a cream-colored lacquer [ΧΗ NMR spectrum (300 MHz , CDC13, δ in ppm) : 2.77 (split t, J = 7 and 2 Hz : 2H) ; 3.40 (split t, J = 7 and 2 Hz : 2H) ; 3.98 (mt : 1H) ; 4.21 (s : 1H) ; from 4.85 to 5.15 (unresolved complex : 1H) ; from 7.20 to 7.35 (mt : 8H) ; "7.57 (d, J = 8.5 Hz : 1H) ; 7.65 (dd, J = 8.5 and 2 Hz : 1H) ; 7.93 (d, J = 2 Hz : 1H) ] .
Example 8 By carrying out the .operation according to the procedure for Example 1, but starting with 121 mg of 3-cyanophenylsulfonyl chloride, 21 mg of N- { 1- [bis ( 4-chlorophenyl) methyl] azetidin-3-yl } -3-cyanophenylsulfonamide are obtained in the form of a cream-colored lacquer [XH NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.76 (split t, J = 7 and 2 Hz : 2H) ;· 3.39 (split t, J = 7 and 2 Hz : 2H) ; 3.99 (mt : 1H) ; 4.21 (s : 1H) ; from 4.80 to 5.60 (very broad unresolved complex ■: 1H) ; from 7.15 to 7.35 (mt : 8H) ; 7.65 (t, J = 8 Hz : 1H) ; 7.86 (broad d, J = 8 Hz : 1H) ; 8.05 (broad d, J = 8 Hz : 1H) ; 8.13 (broad s : 1H) ] .
Example 9 By carrying out the operation according to the procedure of Example 1, but starting with 142 mg of 2 , 5-dimethoxyphenylsulfonyl chloride, 31 mg of N- { 1- [bis (4-chlorophenyl ) methyl ]azetidin-3-yl}- 2 , 5-dimethoxyphenylsulfonamide are obtained in the form of a cream-colored lacquer [1H NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.73 (split t, J = 7 and 2 Hz : 2H) ; 3.27 (split t, J = 7 and 2 Hz : 2H) ; 3.80 (s : 3H) ; from 3.85 to 4.00 (mt : 1H) ; 3.94 (s : 3H) ; 4.19 (s : 1H) ; 5.32 (d, J = 8 Hz :· 1H) ; 6.94 (d, J = 9 Hz :" 1H) ; 7.05 (dd, J = 9 and 3 Hz : 1H) ; 7.23 (mt : 8H) ; 7.40 (d, J = 3 Hz : 1H) ] .
Example 10 By carrying out the operation according to the procedure of Example 1, but starting with 147 mg.of 3-trifluoromethylphenylsulfonyl chloride, 8 mg of N- { 1- [bis ( 4-chlorophenyl) methyl ]azetidin-3-yl}-3-trifluoromethylphenylsulfonamide are obtained in the form of a cream-colored lacquer [1H NMR spectrum (300 MHz, CDCI3, δ in ppm) : 2.79 (split t, J = 7 and 2 Hz : 2H) ; 3.41 (split t, J = 7 and 2 Hz : 2H) ; 4.03 (mt : 1H);.4.23 (s : 1H) ; from 4.80 to 5.10 (broad unresolved complex : 1H) ; from 7.20 to 7.35 (mt : 8H) ; 7.68 (t, J = 8 Hz : 1H) ; 7.87 (broad d, J = 8 Hz : 1H) ; 8.05 (broad d, J = 8 Hz : 1H) ; 8.15 (broad s : 1H) ] . 31 Example 11 By carrying out the operation according to the procedure of Example 1, but starting with 136 mg of naphth-2-ylsulfonyl chloride, 20 mg of " N- { 1- [bis ( 4 -chlorophenyl) methyl] azetidin-3-yl } naphth-2-yl-sulfonamide are obtained in the form of a cream-colored lacquer [XH NMR spectrum (400 MHz, CDCI3, δ in ppm) : 2.74 (mt : 2H) ; 3.35 (mt : 2H) ; 4.02 (mt : 1H) ; 4.17 (s : 1H) ; 4.96 (unresolved complex : 1H) ; from 7.10 to 7.30 (mt : 8H) ; 7.64 (mt : 2H) ; 7.78 (dd, J = 7 and 1.5 Hz : 1H) ; 7.90 to 8.05 (mt : 3H) ; 8.41 (broad s : 1H)].
Example 12 By carrying out the operation according to the procedure of Example 1, but starting with 136 mg of naphth-l-ylsulfonyl chloride, 52 mg of N-{l-[bis(4-chlorophenyl ) methyl] azetidin-3-yl} naphth-l-ylsulfonamide are obtained in the form of a cream-colored foam [lH NMR spectrum (300 MHz, CDC13, δ in ppm): 2.63 (split t, J = 7 and 2 Hz : 2H) ; 3.20 (split t, J = 7 and 2 Hz : 2H) ; 3.90 (mt : 1H) ; 4.12 (s : 1H) ; 5.26 (unresolved .complex : 1H) ; 7.16 (mt : 8H) ; 7.52 (t, J = 8' Hz : 1H) ; from 7.55 to 7.75 (mt : 2H) ; 7.95 (d, J = 8.5 Hz : 1H); 8.06 (d, J = 8.5 Hz : 1H) ; 8.23 (dd, J = 7.5 and 1 Hz : 1H) ; 8.64 (d, J = 8.5 Hz : 1H)] .
Example 13 By carrying out the operation according to the procedure of Example 1, but starting with 128 mg of 32 3 , 4 -difluorophenylsulfonyl chloride, 7 mg of N- { 1- [bis (4-chlorophenyl) methyl] azetidin-3-yl}-3, 4-difluorophenylsulfonamide are obtained in the form of a cream-colored lacquer [lH NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.76 (broad t, J = 7.5 Hz : 2H) ;. 3.39 (broad t, J = 7.5 Hz : 2H) ; 3.98 (mt : 1H) ; 4.20 (broad s : 1H) ; from 4.85 to 5.25 (broad unresolved complex : 1H) ; from 7.15 to 7.35 (mt : 9H) ; from 7.55 to 7.75 (mt : 2H) ] . ■ Example 14 By 'carrying out the operation according to the procedure of Example 1, but starting with 108 mg of l-methylimidazol-4-ylsulfonyl chloride, 22 mg of N-{l-[bis(4 -chlorophenyl) methyl] azetidin-3-yl}-l-methyl-l-tf-imidazol-4-ylsulfonamide are obtained in the form' of a cream-colored foam [1H NMR spectrum (300 MHz, CDCI3, with addition of a few drops of CD3COOD d4 , δ in ppm) : 3.22 (mt : 2H) ; 3.67 (mt : 2H) ; 3.74 (s : 3H) ; 4.10 (mt : 1H); 4.65 (broad s : 1H) ; 7.27 (mt : 8H) ; 7.47 (broad d, J = 1 Hz : 1H) ; 7.53 (broad d, J = 1 Hz : 1H) ] .
Example 15 By carrying out the operation according to the procedure of Example 1, but starting with 152 mg of 4 -acetamido-3-chlorophenylsulfonyl chloride, 69 mg of N-[4-(N-{l-[bis(4 -chlorophenyl ) methyl ] azetidin-3-yl } sulfamoyl ) -2-chlorophenyl ] a'cetamide are obtained in the form of a cream-colored foam [XH NMR spectrum (300 33 MHz, CDCI3, δ in ppm) : 2.30 (s : 3H) ; 2.73 (mt : 2H) ; 3.38 (mt : 2H) ; 3.97 (mt : 1H) ; 4.19 (s : 1H) ; 7.24 (s : 8H) ; 7.70 (dd, J = 7 and 1.5 Hz : 1H) ; 7.78 (broad s : 1H) ; 7.86 (d, J = 1.5 Hz : 1H) ; 8.61 (d, J = 7 Hz : 1H)] .
Example 16 0.79 cm3 of triethylamine is added, at room temperature under an argon atmosphere, to a solution of 0.7 g of 1- [bis ( 4 -chlorophenyl ) methyl] azetidin-3-ylamine in 25 cm3 of dichloromethane . The mixture is cooled to around 0°C before adding thereto a solution of 1.2 g of pyrid-3-ylsulfonyl chloride in 25 cm3 of dichloromethane, and then it is stirred at room temperature for 16 hours. The reaction mixture is diluted with 50 cm3 of dichloromethane and is then washed with twice 25 cm3 of distilled water. The organic phase is dried over magnesium sulfate, filtered and concentrated to dryness under reduced . pressure (2.7 kPa) . The residue obtained, is purified by flash chromatography on silica gel [eluant: dichloromethane/methanol (97.5/2.5 by volume)] . 0.7 g of N- { 1- [bis ( 4 -chlorophenyl ) methyl ]azetidin-3-yl}pyrid-3-ylsulfonamide is obtained in the form of a cream-colored foam which solidifies in the presence of isopropanol into a cream-colored powder melting at 164°C.
Pyrid-3-ylsulfonyl chloride may be prepared according to the method described by Breant, P. et al., Synthesis, 10, 822-4 (1983) .
Example 17 0.214 g of 4-fluorophenylsulfonyl chloride and 0.28 cm3 of triethylamine are added, at room temperature under an argon atmosphere, to a solution of 0.307 g of 1- [bis ( 4-chlorophenyl) methyl] azetidin-3-ylamine in 10 cm3 of dichloromethane . After stirring for 16 hours at room temperature, the reaction mixture is washed with 10 cm3 of distilled water, dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) . The residue obtained is purified by flash chromatography on silica gel [eluant: dichloromethane/ethyl acetate (100/0 to 95/5 by volume) gradient]. 0.18 g of N- { 1- [bis ( 4 -chlorophenyl ) methyl] azetidin-3-yl } -4 -fluorophenylsul fonamide is obtained in the form of a white foam [XH NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.74 (broad t, J = 7.5 Hz : 2H) ; 2.39 (broad t, J = 7.5 Hz : 2H) ; 3.98 (mt : 1H) ; 4.20 (s : 1H) ; 4.79 (d, J = 9 Hz : 1H) ; from 7.10 to 7.35 (mt : 10H) ; 7.86 (mt : 2H) ] .
Example 18 By carrying out the operation according to the procedure for Example 17, but starting with 0.25 g of quinol-8-ylsulfonyl chloride, 0.36 g of N-{l-[bis(4-chlorophenyl) methyl] azetidin-3-yl } quinol -8 -ylsulfonamide is obtained in the form of a white powder [XH NMR spectrum (300 MHz , CDC13, δ in ppm) : 2.63 (split t, J = 7 and 2 Hz : 2H) ; 3.16 (split t, J = 7 and 2 Hz : 2H) ; 3.98 (mt : 1H) ; 4.11 (s : 1H) ; 6.77 ( d, J = 8 Hz : 1H) ; 7.15 (mt : 8H) ; 7.61 (dd, J = 8 and 4 Hz : 1H) ; 7.64 (dd, J = 8 and 7.5 Hz) : 1H) ; 8.06 (dd, J = 8 and 1.5 Hz : 1H) ; 8.30 (dd, J = 8 and 1.5 Hz : 1H); 8.40 (dd, J = 7.5 and 1.5 Hz : 1H) ; 9.09 (dd, J = 4'and 1.5 Hz : 1H)].
Example 19 By carrying out the operation according to the procedure of Example 17, but starting with 0:14 cm3 of phenylsulfonyl chloride, 0.35 g of N-{l-[bis(4-chlorophenyl ) methyl ]azetidin-3-yl} phenylsulfonamide is obtained in the form of a white powder [1H NMR spectrum (300 MHz, CDC13, δ in ppm): 2.75 (broad t, J = 7.5 Hz : 2H) ; 3.40 (broad t, J = 7.5 Hz : 2H) ; 4.03 (mt : 1H) ; . 4.22 (s : 1H) 4.79 (d, J = 10 Hz : 1H) ; 7.31 (s : 8H) ; from 7.45 to 7.65 (mt : 3H) ; 7.87 (broad d, J = 7.5 Hz : 2H) ] .
Example 20 By carrying out the operation according to the procedure of Example 17, but starting with 0.21 g of (phenylmethyl ) sulfonyl chloride, 0.27 g of N- { 1- [bis ( 4 -chlorophenyl ) methyl] azetidin-3-yl } (phenyl -methyl ) sulfonamide is obtained in the form of a white powder [XH NMR spectrum (400 MHz, CDC13, δ in ppm) : 2.76 (split t, J = 7 and 2 Hz : 2H) ; 3.41 (split t, J = 7 and 2 Hz : 2H) ; 3.85 (mt : 1H) ; 4.20 (s : 1H) ; 4.23 (s 36 : 2H) ; 4.46 (d, J = 9 Hz : 1H) ; from 7.25 to 7.45 (mt : 13H)] .
Example 21 By carrying out the operation according to the procedure of Example 17, but starting with 0.42 g of 3 , 5-difluorophenylsulfonyl chloride in 30 cm3 of dichloromethane and washing the organic phase with twice 20 cm3 of distilled water. After purification by flash chromatography on silica gel [eluant: dichloromethane/methanol (100/0 to 95/5 by volume) gradient], 0.1 g of N- { 1- [bis ( 4 -chlorophenyl ) methyl ] -azetidin-3-yl}-3, 5-difluorophenylsulfonamide is obtained in the form of a yellow powder [1H NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.77 (split t, J = 7 and 2 Hz : 2H) ; 3.41 (split t, J = 7 and 2 Hz : 2H) ; 4.01 (mt : 1H) ; 4.21 (s : 1H) ; 4.90 (d, J = 9 Hz : 1H) ; 7.02 (tt, J = 8.5 and 2.5 Hz : 1H) ; from 7.20 to 7.35 (mt : 8H) ; 7.38 (mt : 2H) ] . 3 , 5-Difluorophenylsulfonyl chloride may be prepared according to the method described in Patent FR 9615887.
Example 22 By carrying out the operation according to the procedure of Example 21, but starting with 0.21 g of pyrid-2-ylsulfonyl chloride and 0.17 cm3 of triethylamine and washing the organic phase with twice 30 cm3 of distilled water. After purification by flash chromatography on silica gel [eluant: 37 dichloromethane/methanol (100/0 to 98/2 by volume) gradient ], 0.3 g of N- { 1- [bis ( 4 -chlorophenyl ) methyl ] -azetidin-3-yl } pyrid-2-sulfonamide is obtained in the form of a white powder [XH NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.78 (split t, J = 7 and 2 Hz : 2H) ; 3.35 (split t, J = 7 and 2 Hz : 2H) ; 4.12 (mt : 1H) ; 4.20 (s: 1H) ; 5.30 (d, J = 9 Hz : 1H) ; from 7.15 to 7.35 (mt : 8H) ; 7.47 (ddd, J = 7.5 and 5 and 1 Hz : 1H) ; 7.90 (split t, J = 7.5 and 2 Hz; 1H) ; 7.98 (broad d, J = 7.5 Hz : 1H) ; 8.65 (broad d, J = 5 Hz : 1H) ] .
Pyrid-2-ylsulfonyl chloride may be prepared according to the method described by Corey, E.J. et al., J. Org. Chem. (1989), 54(2), 389-93.
Example 23 0.104 cm3 of pyrrolidine is added, at room temperature, to 0.24 g of N- { 1- [bis ( 4-chlorophenyl ) -methyl] azetidin-3-yl}- (3, 5-di fluorophenyl ) sulfonamide in solution in 6 cm3 of dimethyl sulfoxide and then' the mixture is heated for 18 hours at 90°C. The reaction mixture is diluted with 30 cm3 of dichloromethane and washed with three times 30 cm3 of distilled water. The organic phased is dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) . The residue is purified by flash chromatography on silica gel, eluting with dichloromethane. 50 mg of N- { 1- [bis ( 4-chlorophenyl ) -methyl] azetidin-3-yl } - ( 3-f1uoro-5-pyrrolidin-1-ylphenyl) sulfonamide are thus obtained in the form of a 38 white powder [XH NMR spectrum (600 MHz , CDC13 with addition of a few drops of CD3COOD d4, δ in ppm) : 2.04 (mt : 4H) ; from 3.20 to 3.35 (mt : 6H) ; 3.60 (t, J = 8.5 Hz : 2H) ; 4.14 (mt : 1H) ; 4.57 (s : 1H) 6.31 (broad d, J = 11.5 Hz : 1H) 6.70 (broad d, J = 8.5 Hz : 1H) ; 6.72 (broad s : 1H) ; from 7.20 to 7.35 (mt : 8H) ] .
Example 24 A solution of 0.26 g of N- ( 1- [bis ( 4-chloro-phenyl ) methyl] azetidin-3-yl} -4-fluorophenylsulfonamide in 5 cm3 of tetrahydrofuran ..is added, at room temperature under an argon atmosphere, to a suspension of 20.5 mg of 80% sodium hydride in 10 cm3 of tetrahydrofuran . After stirring for 1 hour at around 20°C, 60 mm3 of iodomethane are added and then after stirring for an additional 16 hours, the suspension is supplemented with 30 cm of ethyl acetate and 20 cm of distilled water. The organic phase is dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) . The residue is purified by flash chromatography on silica gel [eluant: cyclohexane/ethyl acetate (90/10 by volume) ] . 19 mg of N- { 1- [bis (4-chlorophenyl) methyl] azetidin-3-yl}-N-methyl-4-fluorophenylsulfonamide are thus obtained in the form of a white powder [XH NMR spectrum (300 MHz, CDC13/ δ in ppm): 2.69 (s : 3H) ; 3.02 (split t, J = 7 and 2 Hz : 2H) ; 3.35 (split t, J = 7 and 2 Hz : 2H) ; 39 3.91 (mt : 1H) ; 4.27 (s : 1H) ; from 7.15 to 7.35 (mt : 10H) ; 7.75 (dd, J = 9 and 5 Hz : 2H) ] .
Example 25 By carrying out the operation according, to the procedure of Example 24, but starting with 0.25 g of N- { 1- [bis ( 4-chlorophenyl ) methyl ] azetidin-3-yl } -quinol-8-ylsulfonamide and 18 mg of 80% sodium hydride. After purification by flash chromatography on silica gel [eluant: cyclohexane/ethyl acetate (80/20 by volume)], 70 mg of N- {1- [bis ( 4-chlorophenyl ) -methyl ] azetidin-3-yl } -N-methylquinol- 8 -yl sulfonamide are obtained [XH N R spectrum (300 MHz, CDC13, δ in ppm) : from 3.00 to 3.10 (mt : 2H) ; 3.05 (s : 3H) ; 3.35 (mt : 2H) ; 4.27 (s : 1H) ; 4.93 (mt : 1H) ; from 7.15 to 7.35 (mt : 8H) ; 7.50 (dd, J = 8.5 and 4 Hz : 1H) ; 7.62 (dd, J = 8 and 8.5 Hz : 1H) ; 8.03 (dd, J = 8.5 and 1.5 Hz : 1H) ; 8.22 (dd, J = 8.5 and 1.5 Hz : 1H) ; 8.48 (dd, J = 8 and 1.5 Hz : 1H) ; 8.98 (dd, J = 4 and 1.5 Hz : 1H) ] .
Example 26 By carrying out the operation according to the procedure of Example 24, but starting with 0.21 g of N- ( 1- [bis (4-chlorophenyl) methyl] azetidin-3-yl } -phenylsulfonamide , 17 mg of 80% sodium hydride and introducing iodomethane in two portions at an interval of 3 hours. 80 mg of N- { 1- [bis ( 4 -chlorophenyl ) -methyl] azetidin-3-yl } -N-methylphenylsulfonamide are thus obtained in the form of a white lacquer [lR NMR 40 spectrum (300 MHz , CDC13, δ in ppm) : 2.70 (s : 3H) ; 3.03 (broad t, J = 7.5 Hz : 2H) ; 3.37 (broad t, J = 7.5 Hz : 2H) ; 3.94 (mt : 1H) ; 4.28 (s : ,1H) ; from 7.20 to 7.35 (mt : 8H) ; from 7.45 to 7.65 (mt : 3H) ; 7.74 (broad d, J = 8 Hz : 2H) ] .
Example 27 By carrying out the operation according to the procedure of Example 26, but starting with 0.17 g of N- { 1- [bis ( 4-chlorophenyl ) methyl] azetidin-3-yl } -(phenylmethyl) sulfonamide, 14 mg of 80% sodium hydride and maintaining stirred for 48 hours- at 20°C. After-purification by flash chromatography on silica gel [eluant: dichloromethane/ethyl acetate (95/5 by volume)], 120 mg of N- ( 1- [bis ( 4 -chlorophenyl ) -methyl] azetidin-3-yl } -N-methyl (phenylmethyl) sulfonamide are obtained in the form of a white foam [1H NMR spectrum (300 MHz, CDC13, δ in ppm): 2.81 (s : 3H) ; 2.88 (split t, J = 7 and 2 Hz : 2H) ; 3.16 (split t, J = 7 and 2 Hz : 2H) ; from 4.10 to 4.25 (mt : 4H) ; from 7.20 to 7.40 (mt : 13H) ] .
Example 28 A solution of 0.307 g of 1- [bis ( 4 -chlorophenyl ) methyl ] azetidin-3-ylamine is added dropwise, at room temperature, to a solution of 0.412 g of 1, 3-benzenedisulfonic acid dichloride and 0.165 cm3 of triethylamine in 10 cm3 of acetonitrile . After stirring for 3 hours at room temperature, 0.28 cm3 of a 20% solution of ammonia is added and the reaction mixture 41 is left at room temperature. After 18 hours, the mixture is filtered and concentrated to dryness under reduced pressure (2.7 kPa). After chromatography on a silica gel column (particle size 0.06-0.200 mm, height 35 cm, diameter 2 cm) , eluting under an argon pressure of 0.9 bar with dichloromethane and then a mixture of dichloromethane + 1% methanol and then a mixture of dichloromethane + 2% methanol by volume and collecting 30-cm3 fractions, fractions 23 to 34 are combined and concentrated to dryness under reduced pressure (2.7 kPa) to give 90 mg of N- { 1- [bis ( 4-chlorophenyl ) -methyl ] azetidin-3-yl } -3-sulfamoylphenylsulfonamide in the form of a white solid [ H NMR spectrum (300. MHz , CDC13, δ in ppm) : 2.78 (broad t, J = 7 Hz : 2H) ; 3.35 (broad t, J = 7 Hz : 2H) ; 4.01 (mt : 1H) ; 4.24 (s : 1H) ; 5.27 (unresolved complex : 2H) ; 5.61.J unresolved complex : 1H) ; from 7.15 to 7.35 (mt : 8H) ; 7.67 (t, J = 8 Hz : 1H) ; 8.04 (broad d, J = 8 Hz : 1H) ; 8.12 ' (broad d, J = 8 Hz : 1H) ; 8.49 (broad s : 1H) ] .
Example 29 0.031 cm3 of diisopropylcarbodiimide , a solution of 30 mg of 1- [bis ( 4 -chlorophenyl ) -methyl ] azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane, and 3 cm3 of anhydrous dichloromethane are added to a solution of 80.1 mg of benzenesulfonylacetic acid, 27 mg of hydroxybenzotriazole in solution in 0.5 cm3 of dimethylformamide under an inert argon atmosphere, at a 42 temperature in the region of 23°C. After 17 hours at a temperature in the region of 23°C, the reaction mixture is loaded onto a 3-cm3 SPE cartridge containing 1 g of SCX phase preconditioned with methanol. After washing with twice 5 cm3 of methanol and then 4 cm3 of 0.1 N ammoniacal methanol, the expected product is eluted with 4 cm3 of 1 N ammoniacal methanol. The fraction containing the expected product is evaporated under an air stream at a temperature in the region of 45°C and then dried under reduced pressure (1 mbar) at a temperature in the region of 40°C. 2-Benzenesulfonyl-N-{ 1- [bis ( 4 -chlorophenyl) methyl] azetidin-3-yl }.acetamide is thus obtained in the form of a white solid [XH NMR spectrum (500 MHz , CDC13, δ in ppm) : 2.96 (mt : 2H) ; 3.51 (mt : 2H) ; 4.00 (s : 2H) ; 4.34 (unresolved complex : 1H) ; 4.48 (mt : 1H) ; 7.10 (unresolved complex : 1H) ; from 7.20 to 7.45 (mt : 8H) ; 7.57 (t, J = 8 Hz : 2H) ; 7.70 (t, J = 8 Hz : 1H) ; 7.90 (d, J = 8 Hz : 2H) ] .
Example 30 0.031 cm3 of diisopropylcarbodiimide , a solution of 30 mg of 1- [bis ( 4-chlorophenyl ) -methyl ] azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane, and 3 cm3 of anhydrous dichloromethane are added to a solution of 85.7 mg of toluenesulfonylacetic acid, 27 mg of hydroxybenzotriazole in solution in 0.5 cm3 of dimethylformamide under an inert argon atmosphere, at a temperature in the region of 23°C. After 17 hours at a 43 temperature in the region of 23°C, the reaction mixture is loaded onto a 3 -cm3 SPE cartridge containing 1 g of SCX phase preconditioned with methanol. After washing with twice 5 cm3 of methanol and then 4 cm3 of 0.1 N ammoniacal methanol, the expected product is eluted with 4 cm3 of 1 N ammoniacal methanol. The fraction containing the expected product is evaporated under an air stream at a temperature in the region of 45°C and then dried under reduced . pressure (1 mbar) at a temperature in the region of 40°C. N- {1- [bis (4-chlorophenyl ) methyl ] -azetidin-3 -yl } -2- ( toluene-4-sulfonyl ) acetamide is obtained in the form of a yellow lacquer ["'H MR spectrum (500 MHz, CDC13, δ in ppm) : 2.85 (t, J = 7 Hz : 2H) ; 3.07 (s : 3H) ; 3.48 (t, J = 7 Hz : 2H) ; 4.24 (s : 1H) ; 4.49 (mt : 1H) ; 7.19 (broad d, J = 6 Hz : 1H) ; from 7.20 to 7.40 (mt : 8H) ; 8.40 (s : 1H)].
Example 31 By carrying out the operation according to the procedure of Example 30, starting with 85.7 mg of 3 -chloro-4-methylsulfonythiophene-2-carboxylic acid, 27 mg of hydroxybenzotriazole in solution in 0.5 cm3 of dimethylformamide, 0.031 cm3 of diisopropylcarbodiimide, a solution of 30 mg of 1- [bis ( 4-chlorophenyl ) methyl ] -azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane, and 3 cm3 of anhydrous dichloromethane, ( 3-chloro-4-methylsulfonylthiophene-2 -carboxy) -{1-bis (4-chlorophenyl) methyl] azetidin-3 -yl.} amide is 44 obtained in the form of a yellow lacquer [1H NMR spectrum (500 MHz, CDCI3, δ in ppm) : 2.44 (s : 3H) ; '2.96 (unresolved complex : 2H) ; 3.52 (unresolved complex : 2H) ; 3.98 (s : 2H) ; 4.35 (unresolved complex : 1H) ; 4.49 (mt : 1H) ; from 7.00 to 7.30 (broad unresolved complex : 1H) ; from 7.20 to 7.45 (mt : 10H) ; 7.76 (d, J = 8 Hz : 2H) ] .
Example 32 By carrying out the operation according to the procedure of Example 30, starting with 96.1 mg of 3- (2-phenylethylenesulfonyl) propionic acid, 27 mg of hydroxybenzotriazole in solution in .0.5 cm3 of dimethylformamide, 0.031 cm3 of diisopropylcarbodiimide , a solution of 30 mg of 1- [bis ( 4 -chlorophenyl ) methyl] -azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane , and 3 cm3 of anhydrous dichloromethane, N- { 1- [bis ( 4 -chlorophenyl) methyl ]azetidin-3-yl}-3-(2-phenylethylenesulfonyl ) propionamide is obtained in the form of a white foam [XH NMR spectrum (500 MHz, CDCI3, δ in ppm) : 2.64 (t, J = 7 Hz : 2H) ; 2.88 (unresolved complex : 2H) ; 3.33 (t, J = 7 Hz : 2H) ; 3.49 (unresolved complex : 2H) ; 4.29 (unresolved complex : 1H) ; 4.48 (mt : 1H) ; from 5.90 to 6.15 (broad unresolved complex : 1H) ; 6.41 (d, J = 12 Hz : 1H) ; 7.17 (d, J = 12 Hz : 1H) ; from 7.20 to 7.35 (mt : 8H) ; 7.41. (mt : 3H) ; 7.64 (mt : 2H) ] .
Example 33 45 By carrying out the operation according to the procedure of Example 31, starting with 58.5 mg of 4-methylsulfonylbenzoic acid, 26.4 mg of hydroxybenzotriazole in solution in 0.5 cm3 of dimethylformamide, 0.0302 cm3 of diisopropyl-carbodiimide, a solution of 30 mg of l-[bis(4-chlorophenyl ) methyl ] azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane , and 3 cm3 of anhydrous -dichloromethane , N- { 1- [bis ( 4 -chlorophenyl ) -methyl] azetidin-3-yl } -4-methylsulfonylbenzamide is-obtained in the form of a white crystals [2Η NMR spectrum (300 MHz , CDC13, δ in ppm) : 3.03 (mt : 2H) ; 3.09 (s : 3H) ; 3.61 (broad t, J = 1.5 Hz : 2H) ; 4.35 (s : 1H) ; 4.73 (mt : 1H) ; 6.55 (broad d, J = 7.5 Hz : 1H) ; from 7.20 to 7.35 (mt : 8H) ; 7.96 (d, J = 8 Hz : 2H) ; 8.03 (d, J = 8 Hz : 2H) ] .
Example 34 By carrying out the operation according to the procedure of Example 31, starting with 58.5 mg of 3-phenylsulfonylpropionic acid, 26.4 mg of hydroxybenzotriazole in solution in 0.5 cm3 of dimethylformamide, 0.0302 cm3 of diisopropyl-carbodiimide, a solution of 30 mg of l-[bis(4-chlorophenyl ) methyl] azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane, and 3 cm3 of anhydrous dichloromethane, N- { 1- [bis ( 4 -chlorophenyl ) -methyl] azetidin-3-yl} -4 -methanesulfonylbenzamide is obtained in the form of a lacquer [XH NMR spectrum (300 MHz, CDCI3, δ in ppm) : 2.71 (t, J = 7.5 Hz : 2H) ; 2.86 (mt : 2H) ; from 3.40 to 3.55 (mt : 4H) ; 4.26 (s : 1H); 4.45 (mt : 1H) ; 6.22 (broad d, J = 7.5 Hz : 1H) ; from 7.20 to 7.35 (mt : 8H) ; 7.59 (broad t, J = 7.5 Hz : 2H) ; 7.69 (tt, J = 7.5 and 1.5 Hz : 1H) ; 7.93 (broad d, J = 7.5 Hz : 2H) ] .
Example 35 By carrying out the operation according to the procedure of Example 31, starting with 60.2 mg of 5-methylsulfonylthiophene-2-carboxylic acid, 26.4 mg of hydroxybenzotriazole in solution in 0.5 cm3 of dimethylformamide , 0.0302 cm3 of diisopropyl-carbodiimide , a solution of 30 mg of l-[bis(4-chlorophenyl ) methyl ] azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane , and 3 cm3 of anhydrous dichloromethane , ( 5-methylsulfonylthiophene-2-carboxy ) -{ 1- [bis ( 4 -chlorophenyl ) methyl] azetidin-3-yl} amide is obtained in the form of white crystals [XH NMR spectrum (300 MHz, CDCI3, δ in ppm) : 3.03 (mt .: 2H) ; 3.21 (s : 3H) ; 3.57 (dd, J = 8 and 7.5 Hz : 2H) ; 4.34 (s : 1H) ; 4.67 (mt : 1H) ; 6.40 (broad d, J = 7.5 Hz : 1H) ; from 7.20 to 7.35 (mt ' : 8H) ; 7.48 (d, J = 4 Hz : 1H) ; 7.67 (d, J = 4 Hz : 1H) ] .
Example 36 By carrying out the operation according to the procedure of Example 31, starting with 71.9 mg of 5-methylsulfonyl-3-methyl-4 -vinyl thiophene-2 -carboxylic acid, 26.4 mg of hydroxybenzotriazole in solution in 47 0.5 cm3 of dimethyl formamide, 0.0302 cm3 of diisopropylcarbodiimide, a solution of 30 mg of 1- [bis (4-chlorophenyl) methyl] azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane , and 3 cm3 of anhydrous dichloromethane, ( 5-methylsul fonyl-3-methyl-4-vinylthiophene-2-carboxy) { 1- [bis- (4-chlorophenyl) -methyl] azetidin-3-yl } amide is obtained in the form of a white powder [XH NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.47 (s : 3H) ; 2.97 (mt : 2H) ; 3.14 (s : 3H) ; 3.57 (dd, J = 8 and 7.5 Hz : 2H) ; 4.32 (s : 1H) ; 4.65 (mt : 1H) ; 5.69 (dd, J = 18 and 1 Hz : 1H) ; 5.77 (dd, J = 12 and 1 Hz : 1H) ; 6.30 (broad d, J = 7.5 Hz : 1H) ; 6.96 (dd, J = 18 and 12 Hz : 1H) ; from 7.20 to 7.35 (mt : 8H) ] .
Example 37 By carrying out the operation according to the procedure of Example 31, starting with 62.6 mg of 3-methylsulfonylmethylbenzoic acid, 26.4 mg of hydroxybenzotriazole in solution in 0.5 cm3 of dimethylformamide , 0.0302 cm3 of diisopropylcarbodiimide, a solution of 30 mg of l-[bis(4-chlorophenyl) methyl] azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane, and 3 cm3 of anhydrous dichloromethane, ( 5-methylsulfonyl-3-methyl-4 -vinylthiophene-2-carboxy) ( 1- [bis (4-chlorophenyl ) -methyl] azetidin-3-yl } amide is obtained in the form of white needles NMR spectrum (300 MHz, (CD3)2SO d6 with addition of CDC13, δ in ppm) : 2.84 (s : 3H) ; 3.02 48 (broad t, J = 7 Hz : 2H) ; 3.48 (t, -J = 7 Hz : 2H) ; 4.38 (s : 3H) ; 4.53 (mt : 1H) ; 7.21 (d, J = 8 Hz : 4H) ; 7.34 (d, J = 8 Hz : 4H) ; 7.40 (t, J = 7.5 Hz : 1H) ; 7.53 (broad d, J = 7.5 Hz : 1H) ; 7.84 (broad d, J = 7.5 Hz : 1H).; 7.89 (broad s : 1H) ; 8.54 (d, J = 7 Hz : 1H) ] .
Example 38 (RS) -N- {1- [ ( 4-chlorophenyl )pyridin-3 -yl-methyl] azetidin-3-yl} -3 , 5-difluorobenzenesulfonamide may be obtained in the following manner': 0.46 g of potassium carbonate and 41 mg of potassium iodide are added to a mixture of 0.3 g of (RS) -3- [bromo- ( 4-chlorophenyl ) methyl] pyridine hydrobromide and 0.28 g of N-azetidin-3-yl-3 , 5-difluorobenzenesulfonamide hydrochloride in 20 cm3 of acetonitrile, and then the mixture is heated under reflux for 4 hours. After cooling to a temperature in the region of 20°C, the insoluble matter is removed by filtration and then the mixture is concentrated to dryness under reduced pressure. The residue obtained is taken up in 100 cm3 of ethyl acetate." The organic phase is washed with twice 50 cm3 of water, dried over magnesium sulfate in the presence of animal charcoal, filtered on Celite, and then concentrated to dryness under reduced pressure. 230 mg of an orange-colored solid are obtained, which solid is dissolved in a cyclohexane-ethyl acetate mixture (50-50 by volume mixture) and purified by chromatography under pressure on a cartridge of 10 g of silica with the same eluent mixture, with a flow rate 49 of 6 cm3 /minute . Fractions 22 to 56 are combined and concentrated ' to dryness under reduced pressure. 100 mg of (RS) -N- {1- [ ( 4-chlorophenyl )pyridin-3 -yl-methyl] azetidin-3-yl} -3 , 5-difluorobenzenesulfonamide are thus obtained in the form of a pale yellow foam melting at 70°C [ΧΗ NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.81 (mt : 2H) ; 3.42 (mt : 2H) ; 4.03 (mt : 1H) ; 4.29 (s : 1H) ; 5.43 (d, J = 9 Hz : 1H) ; 7.01 (tt, J = 9 and 2.5 Hz : 1H) ; 7.22 (dd, J = 8 and 5 Hz : 1H) ; 7.28 (mt : 4H) ; 7.36 (mt : 2H) ; 7.62 (broad d, J = 8 Hz : 1H) ; 8.48 (dd, J = 5 and 1 Hz : 1H) ; 8.59 (d, J = 1 Hz : 1H)].
(RS) -3- [bromo- ( 4-chlorophenyl ) methyl ] pyridine is obtained in the following manner: 3.5 cm3 of a 48% hydrobromic acid solution in acetic acid and 1 cm3 of acetyl bromide are added to 1.5 g of (4-chlorophenyl) -pyridin-3-ylmethanol . The amber-colored mixture thus obtained is heated under reflux for 4 hours and then cooled to 20 °C, and concentrated to dryness at 40°C under 2.7 kPa, giving 1.53 g of (RS) -3- [bromo- (4-chlorophenyl) methyl] pyridine (Rf = 75/90, 254 nrn, silica plates, reference 1.05719, Merck KGaA, 64271 Darmstadt, Germany) .
N-azetidin-3-yl-3 , 5-difluorobenzene-sulfonamide hydrochloride may be prepared in the following manner: in a 2000 cm3 hydrogenator, a solution of 7.5 g of N- (l-benzhydrylazetidin-3-yl) -3 , 5-difluorobenzenesulfonamide in a mixture of 10 cm3 of 50 concentrated hydrochloric acid (36% by weight), 1.7 cm3 of acetic acid and 500 cm3 of methanol is hydrogenated in the presence of 4.21 g of palladium hydroxide on carbon (20% by weight of catalyst) under 1.7 bar of hydrogen for about 20 hours. The catalyst is removed by filtration on a bed of Celite and then the filtrate is concentrated to dryness under reduced pressure. The residue obtained is beaten with 100 cm3 of diisopropyl ether for about 16 hours at a temperature in the region of 20°C. The suspension is filtered, and the solid residue is again beaten with 100 cm3 of diethyl ether at a temperature in the region of 20°C. After filtration, the paste obtained is dried under reduced pressure at a temperature in the region of 40°C. 5.52 g of N-azetidin-3-yl-3 , 5-difluorobenzenesulfonamide hydrochloride are thus obtained in the form of a white powder .
N- ( l-benzhydrylazetidin-3-yl) -3 , 5-difluorobenzenesulfonamide may be prepared in the following manner: 5.1 g of 3 , 5-difluorobenzenesulfonyl chloride and then 4.2 cm3 of triethylamine are successively added to a suspension of 5 g of l-benzhydrylazetidin-3-ylamine in 80 cm3 of dichloromethane, at a temperature in the region of 20°C. After stirring for 20 hours at a temperature in the region of 20°C, 50 cm3 of water are added. The organic phase separated after settling is washed with twice 50 cm3 of water, dried over magnesium sulfate, and concentrated to dryness under reduced pressure. 8.99 g of a yellow oil are thus obtained, which oil crystallizes little by little. 4.5 g of this product is purified by chromatography under pressure on 500 g of Amicon silica (diameter of the particles from 0.020 to 0.045 mm), eluting with a methanol-dichloromethane (1-99 by volume) mixture. The fractions containing the desired product are combined and concentrated to dryness under reduced pressure to give 3.58 g of N- ( l-benzhydrylazetidin-3-yl) -3 , 5-difluorobenzene-sulfonamide in the form of a beige powder..The remaining quantity of the preceding yellow oil is purified under the same conditions and provides 3.92 g of N- ( l-benzhydrylazetidin-3-yl ) -3 , 5-difluorobenzene-sulfonamide in the form of a beige powder. l-Benzhydrylazetidin-3-ylamine may be prepared as described in J. Antibiot., 39(9), 1243-1256, 1986. 3 , 5-Di luorobenzenesulfonyl chloride may be prepared as described in patent: FR2757509.
Example 39 (RS) -N-{1- [ (4-chlorophenyl) pyrimidin-5-yl-methyl] azetidin-3-yl} -3 ; 5-difluorobenzenesulfonamide may be obtained by carrying out the procedure as for the preparation of (RS) -N- { 1- [( 4-chlorophenyl ) pyridin-3-ylmethyl] azetidin-3-yl} -3 , 5-difluorobenzenesulfonamide: starting with 0.64 g of (RS) -5- [bromo- ( 4-chlorophenyl) methyl Ipyrimidine hydrobromide, 0.5 g 52 of N-azetidin-3-yl-3 , 5-difluorobenzenesulfonamide hydrochloride in 20 cm3 of acetonitril, 1.213 g of potassium carbonate and 379 mg of potassium iodide 71 mg of (RS) -N-{1- [ (4-chlorophenyl ) pyrimidin-5-yl-methyl] azetidin-3-yl} -3 , 5-difluorobenzenesulfonamide are thus obtained in the form of a yellow foam [1H NMR spectrum (300 MHz, CDC13, δ in ppm) : 2.83 (mt : 2H) ; 3.46 (mt : 2H) ; 4.03 (mt : 1H) ; 4.30 (s : 1H) ; 5.00 (d, J *= 9 Hz : 1H) ; 7.04 (tt, J = 9 and 2.5 Hz : 1H) ; from 7.20 to 7.35 (mt : 4H) ; 7.37 (mt : 2H) ; 8.69 (s : 2H) ; 9.09 (s : 1H) ] .
(RS) -5- [bromo- ( 4-chlorophenyl ) methyl ] -pyrimidine may be prepared by carrying out the procedure as for the preparation of (RS) -^3- [bromo- ( 4-chlorophenyl) methyl] yridine using, as raw material, ( 4-chlorophenyl ) pyrimidin-5-ylmethanol . (4-Chlorophenyl) pyrimidin-5-ylmethanol may be prepared by carrying out the procedure as for ( 4-chlorophenyl )pyridin-3-ylmethanol, starting with pyrimidine-5-carboxaldehyde and 4-chlorophenylmagnesium bromide.
The medicaments according to the invention consist of a compound of formula (I) or an isomer or a. salt of such a compound, in the pure state or in the form of a composition in which it is combined with any other pharmaceutically compatible product which may be inert or physiologically active. The medicaments 53 according to the invention may be used orally, parenterally, rectally or topically.
As solid compositions for oral administration, tablets, pills, powders (gelatin capsules, sachets) or granules may be used. In these compositions, the active ingredient according to the invention is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under an argon stream. These compositions may also comprise substances other than diluents, for example one or more lubricants such as magnesium stearate or talc, a coloring, a coating (sugar-coated tablets) or a glaze .
As liquid compositions for oral administration, there may be used pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs containing inert diluents such as water, ethanol, glycerol, vegetable oils or paraffin oil.
These compositions may comprise substances other than diluents, for example wetting, sweetening, thickening, flavoring or stabilizing products.
Sterile compositions for parenteral administration may be preferably solutions which are aqueous or nonaqueous, suspensions or emulsions. As solvent or vehicle, there may be used water, propylene glycol, polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate or other suitable organic 54 solvents. These compositions may also contain adjuvants, in particular wetting, isotonizing, emulsifying ,. dispersing and stabilizing agents.
Sterilization may be carried out in several ways, for example by asepticizing filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They may also be prepared in the form of sterile solid compositions which may be dissolved at the time of use in sterile water or. any other injectable sterile medium.
Compositions for rectal administration are suppositories or rectal capsules which contain, in addition to the active product, excipients such as cocoa butter, semisynthetic glycerides or polyethylene glycols.
Compositions for topical administration may be, for example, creams, lotions, collyria, collutoria, nasal drops or aerosols.
In human therapy, the compounds according to the invention are particularly useful for the treatment and/or prevention of psychoses including schizophrenia, anxiety disorders, depression, epilepsy, neurodegeneration, cerebellar and spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheral neuropathies, glaucomas, migraine, Parkinson's disease, Alzheimer's disease, Huntington's chorea, Raynaud's syndrome, tremor, obsessive-compulsive disorder, senile dementia, thymic disorders, 55 Tourette ' s syndrome, tardive dyskinesia, bipolar disorders, cancers, movement disorders induced by medicaments, dystonia, endotoxemic shocks, hemorrhagic shocks, hypotension, insomnia, immunological diseases, multiple sclerosis, vomiting, asthma, appetite disorders (bulimia, anorexia) , obesity, memory disorders, intestinal transit disorders, in weaning from chronic treatments and alcohol or drug abuse (opioids, barbiturates, cannabis, cocaine, amphetamine, phencyclide, . hallucinogens, benzodiazepines for example) , as analgesics or potentiators of the analgesic activity of the narcotic and nonnarcotic drugs .
The doses depend on the desired effect, the duration of the treatment and the route of administration used; they are generally between 5 mg and 1000 mg per day orally for an adult with unit doses ranging from 1 mg to 250 mg of active substance.
In general, the doctor will determine the appropriate dosage depending on the age, weight and any other factors specific to the subject to be treated.
The following examples illustrate the compositions according to the invention: EXAMPLE A Gelatin capsules containing a dose of 50 mg of active product and having the following composition are prepared according to the usual technique: 56 Compound of formula (I) 50 mg Cellulose 18 mg Lactose 55 mg Colloidal silica 1 mg Sodium carboxymethylstarch 10 mg Talc 10 mg Magnesium stearate 1 mg EXAMPLE B Tablets containing a dose of 50 mg of active product and having the following composition are prepared according to the usual technique: - Compound of formula (I) 50 mg - Lactose 104 mg - Cellulose .. 40 mg - Polyvidone 10 mg - Sodium carboxymethylstarch 22 mg - Talc 10 mg - Magnesium stearate 2 mg - Colloidal silica 2 mg - Mixture of hydroxymethylcellulose, glycerin, titanium oxide (72-3.5-24.5) qs 1 finished film- coated tablet containing 245 mg EXAMPLE C An injectable solution containing 10 mg of active product and having the following composition i prepared: 57 - Compound of formula (I) 10 mg - Benzoic acid 80 mg - Benzyl alcohol 0.06 ml - Sodium benzoate 80 mg - Ethanol, 95% 0.4 ml - Sodium hydroxide 24 mg - Propylene glycol 1.6 ml - Water qs 4 ml Material which is outside the scope of the claims does not constitute part of the claimed invention.

Claims (18)

1. l A i compound of formula^ in whic • Ri represents a radical --NHCOR4 or --N(R5)"Y"R6 ; . Y is so2 ; • 2 and R3, which are identical or different, represent either an aromatic radical selected from phenyl, naphthyl and indenyl, these aromatics being unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoro-methoxy, --CO-alk, cyano, "COOH, --COOalk, --CONR7 Re, --CO--NH--NR9 Rio, alkylsulfanyl, alkylsulfinyl, alkyl- sulfonyl, alkylsulfanylalkyl, alkylsulflnylalkyl, alkylsulfonylalkyl, hydroxyalkyl or -alk-NR7 Rs radicals; or a heteroaromatic radical selected from benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3- dihydrobenzothienyl, pyrimidinyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, quinolyl, 1,2,3,4-tetrahydro- isoquinolyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic radicals to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, "COOH, "COOalk, --CO--NH--NR9 Rio, " CONR7 Re, -alk-NRg Rio, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, 59 151209/3 alkylsulfanylalkyl, alkylsulflnylalkyl, alkylsulfonylalkyl or hydroxyalkyl radical; R4 represents a phenyl substituted with -SO2 --R11 ; R5 represents a hydrogen atom or an alkyl radical; 6 represents a phenylalkyl, Het or Ar radical; R7 and Re, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R7 and Re together with the nitrogen atom to which they are attached form a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally further having another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, R9 and Rio, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or alternatively R9 and R1o together with the nitrogen atom to which they are attached form a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally further having another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or -CO-NH2 radicals, Rn represents an alkyl radical, Ar represents a phenyl, naphthyl or indenyl radical, these radicals being optionally substituted with one or more halogen atoms or alkyl, alkoxy, cyano, -CO-alk, -COOH, -COOalk, --CONR12 R13, -CO--NH-NR14 Ri5, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -alk-NRH Ri5, -NRH Ri5, alkylthioalkyl, formyl, hydroxyl, hydroxyalkyl, -O-alk-NH-cycloalkyl, OCF3, CF3, -NH-CO-alk, -SO2 NH2, -NH-COCH3, "NH-COOalk or Het radicals, or alternatively, a fused ring containing a 3-10 membered Het radical is formed on 2 adjacent carbon atoms of said Ar radical, with a dioxymethylene, 60 151209/2 • said Het being an unsaturated or saturated mono- or bicyclic heterocycle having one or more heteroatoms selected from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, alkoxycarbonyl, oxo, hydroxyl, OCF3 or CF3 radicals, the heterocycles that have nitrogen being optionally in their N-oxidized form; • R12 and Ri3, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R12 and R13 together with the nitrogen atom to which they are attached form a 3- to 10- membered saturated mono- or bicyclic heterocycle, optionally further having another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals; • Ri4 and R15, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or alternatively R14 and R15 together with the nitrogen atom to which they are attached form a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally further having another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, - COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, - alk-O-alk or --CO-NH2 radicals, • alk represents an alkyl or alkylene radical, • the alkyl and alkylene radicals and portions and the alkoxy radicals and portions are in the form of a straight or branched chain having 1 to 6 carbon atoms and the cycloalkyl radicals have 3 to 10 carbon atoms, or the optical isomers thereof or pharmaceutically acceptable salts of such compound, with the exception of any compound in which R2 and R3 represent phenyl radicals, Ri represents a radical --N(Rs)--Y--R6, Y is SO2, 61 151209/2 Re represents a methyl radical and R.6 represents a phenyl radical.
2. A compound according to claim 1 wherein, in formula (I), Het represents a heterocycle selected from benzimidazole, benzoxazole, benzothiazole, benzothiophene, cinnoline, thiophene, quinazoline, quinoxaline, quinoline, pyrazole, pyrrole, pyridine, imidazole, indole, isoquinoline, pyrimidine, thiazole, thiadiazole, piperidine, piperazine, pyrrolidine, triazole, furan, tetrahydroisoquinoline, tetrahydroquinoline, said heterocycle being optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, alkoxycarbonyl, oxo, hydroxyl, OCF3 or CF3 radicals.
3. A compound according to claim 1 wherein, in formula (I), • Ri represents a radical --N(Rs)--Y--R6 ; • Y is S02 ; • R2 represents either a phenyl which is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, cyano, -CONR Rs, hydroxyalkyl or -alk-NR7 Rs radicals; or a heteroaromatic radical selected from pyridyl, pyrimidyl, thiazolyl and tbienyl rings, it being possible for these heteroaromatic radicals to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, --CONR7 Rs, -alk-NRg Rio, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl or hydroxyalkyl radical; • R3 represents either a phenyl which is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, cyano, --CONR7 Rs, hydroxyalkyl or -alk-NR7 Rs radicals; or a heteroaromatic radical selected from pyridyl, pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic radicals to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl, 62 151209/2 trifluoromethoxy, --CONR7 Rs, -alk-NR9 Rio, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl or hydroxyalkyl radical, Rs represents a hydrogen atom or an alkyl radical, R6 represents a naphthyl, phenylalkyl, Het or phenyl radical optionally substituted with one or more halogen atoms or alkyl, alkoxy, cyano, -CO-alk, COOalk, -CONR12 R13, -alk-NR14 R15, -NR14 Ri5, hydroxyl, hydroxyalkyl, Het, OCF3, CF3, -NH--CO-alk, --SO2 NH2 or -NH--COOalk radicals, or alternatively, a fused ring containing a 3-10 membered Het radical is formed on 2 adjacent carbon atoms of said phenyl radical, with dioxy methylene, R7 and Rs, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R7 and Rs together with the nitrogen atom to which they are attached form a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally further having another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, R9 and Rio, which are identical or different, represent a hydrogen atom or an alkyl, cycloalkyl, alkylcycloalkyl or hydroxyalkyl radical or alternatively R9 and Rio together with the nitrogen atom to which they are attached form a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally further having another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, oxo or --CO--NH2 radicals, Ri2 and Ri3, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R12 and R13 together with the nitrogen atom to which they are attached form a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally further having another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals; 63 151209/2 • R and R15, which are identical or different, represent a hydrogen atom or an alkyl, cycloalkyl, alkylcycloalkyl or hydroxyalkyl radical or alternatively Ru and R15 together with the nitrogen atom to which they are attached form a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally further having another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, oxo, hydroxyalkyl or -CO-NH2 radicals, • Het represents a 3- to 10-membered unsaturated or saturated mono- or bicyclic heterocycle having one or more heteroatoms selected from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, alkoxycarbonyl, oxo or hydroxyl radicals, the nitrogen-containing heterocycles being optionally in their N-oxidized form, or the optical isomers thereof or pharmaceutically acceptable salts of such compound, with the exception of any compound for which R2 and R3 represent phenyl radicals, Ri represents a radical --N(Rs)--Y--R6, Y is SO2, R5 represents a methyl radical and R6 represents a phenyl radical.
4. A compound according to claim 2 wherein, in formula (I), Het represents a heterocycle selected from benzimidazole, benzoxazole, benzothiazole, benzothiophene, thiophene, quinazoline, quinoxaline, quinoline, pyrrole, pyridine, imidazole, indole, isoquinoline, pyrimidine, thiazole, thiadiazole, furan, tetrahydroisoquinoline and tetrahydroquinoline, these heterocycles being optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, oxo, hydroxyl, OCF3 or CF3 radicals.
5. A compound according to claim 1 wherein, in formula (I), • Ri represents a radical -N(Rs)-Y--R6 ; . Y is S02 ; 64 151209/2 R2 represents either a phenyl which is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, trifluoromethyl, trifluoromethoxy or hydroxyalkyl radicals; or a heteroaromatic radical selected from pyridyl and pyrimidyl rings, it being possible for these heteroaromatic radicals to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl or trifluoromethoxy radical; R.3 represents either a phenyl which is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, trifluoromethyl, trifluoromethoxy or hydroxyalkyl radicals; or a heteroaromatic radical selected from pyridyl and pyrimidyl rings, it being possible for these heteroaromatic radicals to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl or trifluoromethoxy radical, R5 represents a hydrogen atom or an alkyl radical, Re represents a naphthyl, phenylalkyl, Het or phenyl radical optionally substituted with one or more halogen atoms or alkyl, alkoxy, -NR R15, hydroxyl, hydroxyalkyl, OCF3, CF3 or -SO2 NH2 radicals, or alternatively, a fused ring containing a 3-10 membered Het radical is formed on 2 adjacent carbon atoms of said phenyl radical, with dioxymethylene, Ri4 and R15, which are identical or different, represent a hydrogen atom or an alkyl, cycloalkyl, alkylcycloalkyl or hydroxyalkyl radical or alternatively Ru and R15 together with the nitrogen atom to which they are attached form a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally further having another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, oxo, hydroxyalkyl or -CO-NH2 radicals, Het represents a 3- to 10-membered unsaturated or saturated mono- or bicyclic heterocycle containing one or more heteroatoms selected from oxygen, sulfur and nitrogen optionally substituted 65 151209/2 with one or more halogen atoms or alkyl, alkoxy, vinyl, alkoxycarbonyl, oxo or hydroxyl radicals, the heterocycles that have nitrogen being optionally in their N-oxidized form, or the optical isomers thereof or pharmaceutically acceptable salts of such compound, with the exception of any compound in which R2 and R3 represent phenyl radicals, Ri represents a radical -N(R5)-Y-R6, Y is SO2, R5 represents a methyl radical and R6 represents a phenyl radical.
6. A compound according to claim 5 wherein, in formula (I), Het represents a heterocycle selected from benzimidazole, benzoxazole, benzothiazole, benzothiophene, thiophene, quinoline, pyrrole, pyridine, pyrimidine, thiazole, thiadiazole, furan, tetrahydroisoquinoline and tetrahydroquinoline, these heterocycles being optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, oxo, hydroxyl, OCF3 or CF3 radicals.
7. A process for preparing a compound of formula (I) according to claim 1 in which Ri represents a radical --NHCOR4, the process comprising reacting an acid R4 COOH for which R4 has the same meanings as in claim 1 with a derivative of formula: in which R2 and R3 have the same meanings as in claim 1, isolating the product, and optionally converting the product to a pharmaceutically acceptable salt. 66 151209/2
8. A process for preparing a compound of formula (I) according to claim 1 in which Ri represents a radical -N(R5)-Y-R6, the process comprising reacting a derivative of formula: which R2 and R3 have the same meanings as in claim 1 with a derivative Hal-Y-R6 in which Y and R6 have the same meanings as in claim 1 and Hal represents a halogen atom, optionally followed by reacting the product with a derivative Hal-alk, in which Hal represents a halogen atom and alk represents a Cl-6 straight or branched chain alkyl radical to produce the compounds in which R5 is an alkyl radical, isolating the product, and optionally converting the product to a pharmaceutically acceptable salt.
9. A process for preparing a compound of formula (I) according to claim 1. the process comprising reacting a derivative R2 -CHBr-Re in which R2 and R3 have the same meanings as in claim 1 with a derivative of formula: in which Ri has the same meanings as in claim 1, isolating the product, and optionally converting the product to a pharmaceutically acceptable salt.
10. A process for preparing a compound of formula (I) according to claim 1 in which Ri represents a radical -N(R5)--Y--R6 in which R6 is a phenyl 67 151209/2 radical substituted with a hydroxyl radical, the process comprising hydrolyzing a corresponding compound of formula (I) in which Ri represents a radical --N(R5)--Y--R6 in which R6 is a phenyl radical substituted with an alkoxy radical, isolating the product, and optionally converting the product to a pharmaceutically acceptable salt.
11. A process for preparing a compound of formula (I) according to claim 1 in which Ri represents a radical -N(R5)--Y--R6 in which R6 is a phenyl radical substituted with a hydroxy(lC)alkyl radical, the process comprising reacting diisobutylaluminum hydride with a corresponding compound of formula (I) in which Ri represents a radical --N(R5)--Y-R6 in which Re is a phenyl radical substituted with an alkoxycarbonyl radical, isolating the product, and optionally converting the product to a pharmaceutically acceptable salt.
12. A process for preparing a compound of formula (I) according to claim 1 in which Ri represents a radical -N(R5)-Y--R6 in which R6 is a phenyl radical substituted with a 1-pyrrolidinyl radical, the process comprising reacting pyrrolidine with a corresponding compound of formula (I) in which Ri represents a radical --N(Rs)--Y-R6 in which R6 is a phenyl radical substituted with a fluorine atom, isolating the product, and optionally converting the product to a pharmaceutically acceptable salt.
13. A pharmaceutical composition comprising, as an active ingredient, a compound of formula: Ν· 68 151209/4 which • Ri represents a radical --NHCOR4 or --N(R5)--Y"R6, . Y is S02) • R2 and R3, which are identical or different, represent either an aromatic radical selected from phenyl, naphthyl and indenyl, these aromatic radicals being unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoro-methoxy, "CO-alk, cyano, --COOH, - COOalk, --CONR7 Re, "CO--NH--NR9 Rio, alkylsulfanyl, alkylsulfinyl, alkyl- sulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, hydroxyalkyl or -alk-NR7 Rs radicals; or a heteroaromatic radical selected from benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3- dihydrobenzothienyl, pyrimidinyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, quinolyl, 1,2,3,4- tetrahydroisoquinolyl, thiazolyl and thienyl rings, these heteroaromatic radicals being unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, "COOH, -COOalk, -CO"NH"NR9 Rio, " CONR7 Re, -alk-NRg Rio, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or hydroxyalkyl radical, • R4 represents a phenyl substituted with --SO2 "R11, • R5 represents a hydrogen atom or an alkyl radical, • R6 represents a phenylalkyl, Het or Ar radical, • R7 and Re, which are identical or different, represent a hydrogen atom or an alkyl radical or, alternatively, R7 and Rs form, together with the nitrogen atom to which they are attached, a 3- to 10- membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and 69 151209/3 nitrogen and being optionally substituted with one or more alkyl radicals, R9 and Rio, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or, alternatively, R9 and Rio form, together with the nitrogen atom to which they are attached, a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, said heterocycle optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, -COalk, -COOalk, -CO-NHalk, --CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or -CO--NH2 radicals, R11 represents an alkyl, Ar represents a phenyl, naphthyl or indenyl radical, these radicals being optionally substituted with one or more halogen atoms or alkyl, alkoxy, cyano, -CO-alk, -COOH, -COOalk, -CONR12 R13, -CO-NH-NR14 Ri5, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -alk-NRi4 Ri5, -NRH R15, alkylthioalkyl, formyl, hydroxyl, hydroxyalkyl, -O-alk-NH-cycloalkyl, OCF3, CF3, -NH-CO-alk, -SO2 NH2, ~NH-COCH3, -NH-COOalk or Het radicals or, alternatively, a fused ring containing a 3-10 membered Het radical is formed on 2 adjacent carbon atoms of said Ar radical, with a dioxymethylene, said Het being an unsaturated or saturated mono- or bicyclic heterocycle containing one or more heteroatoms selected from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, alkoxycarbonyl, oxo, hydroxyl, OCF3 or CF3 radicals, the nitrogen-containing heterocycles being optionally in their N-oxidized form, R12 and Ri3, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R12 and R13 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally 70 151209/2 containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, • Ri4 and R15, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or alternatively R14 and R15 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, - COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, - alk-O-alk or --CO--NH2 radicals, • alk represents an alkyl or alkylene radical, • the alkyl and alkylene radicals and portions and the alkoxy radicals and portions are in the form of a straight or branched chain and contain 1 to 6 carbon atoms and the cycloalkyl radicals contain 3 to 10 carbon atoms, an optical isomer of such a compound or one of its pharmaceutically acceptable salts.
14. A pharmaceutical composition according to claim 13 wherein, in the compound of formula (I), Het represents a heterocycle selected from benzimidazole, benzoxazole, benzothiazole, benzothiophene, cinnoline, thiophene, quinazoline, quinoxaline, quinoline, pyrazole, pyrrole, pyridine, imidazole, indole, isoquinoline, pyrimidine, thiazole, thiadiazole, piperidine, piperazine, pyrrolidine, triazole, furan, tetrahydroisoquinoline, tetrahydroquinoline, said heterocycle being optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, alkoxycarbonyl, oxo, hydroxyl, OCF3 or CF3 radicals. 71 151209/2
15. A pharmaceutical composition according to claim 13 comprising, as an active ingredient, at least one compound of formula (I) wherein • Ri represents a radical -N(R5)-Y--R6, • Y is S02, • R2 represents either a phenyl which is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, cyano, --CONR7 Rs, hydroxyalkyl or -alk-NR7 Rs radicals; or a heteroaromatic radical selected from pyridyl, pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic radicals to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, -CONR7 Rs, -alk-NR9 R1o, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl or hydroxyalkyl radical, • R3 represents either a phenyl which is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, cyano, -CONR7 Rs, hydroxyalkyl or -alk-NR7 Rs radicals; or a heteroaromatic radical selected from pyridyl, pyrimidyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic radicals to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, --CONR7 Rs, -alk-NR9 Rio, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl or hydroxyalkyl radical, • R5 represents a hydrogen atom or an alkyl radical, • R6 represents a naphthyl, phenylalkyl, Het or phenyl radical optionally substituted with one or more halogen atoms or alkyl, alkoxy, cyano, -CO-alk, COOalk, ~CONR12 R13, -alk-NR R15, - NR14 R15, hydroxyl, hydroxyalkyl, Het, OCF3, CF3, -NH--CO-alk, - SO2 NH2 or -NH--COOalk radicals, or alternatively, a fused ring containing a 3-10 membered Het radical is formed on 2 adjacent carbon atoms of said phenyl radical, with dioxymethylene, 72 151209/2 R7 and Rs, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R7 and Re together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, R9 and Rio, which are identical or different, represent a hydrogen atom or an alkyl, cycloalkyl, alkylcycloalkyl or hydroxyalkyl radical or alternatively R9 and Rio together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, oxo or --CO--NH2 radicals, R12 and R13, which are identical or different, represent a hydrogen atom or an alkyl radical or alternatively R12 and R^ together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl radicals, Ri4 and R15, which are identical or different, represent a hydrogen atom or an alkyl, cycloalkyl, alkylcycloalkyl or hydroxyalkyl radical or alternatively R14 and R15 together form with the nitrogen atom to which they are attached a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more substituents selected from alkyl, oxo, hydroxyalkyl and -CO-NH2 radicals, Het represents a 3- to 10-membered unsaturated or saturated mono- or bicyclic heterocycle containing one or more heteroatoms 73 151209/2 selected from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, alkoxycarbonyl, oxo or hydroxyl radicals, the nitrogen-containing heterocycles being optionally in their N-oxidized form, an optical isomer of such a compound or one of its pharmaceutically acceptable salts.
16. A pharmaceutical composition according to claim 15 wherein, in the compound of formula (I), Het represents a heterocycle selected from benzimidazole, benzoxazole, benzothiazole, benzothiophene, thiophene, quinazoline, quinoxaline, quinoline, pyrrole, pyridine, imidazole, indole, isoquinoline, pyrimidine, thiazole, thiadiazole, furan, tetrahydroisoquinolme and tetrahydroquinoline, these heterocycles being optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, vinyl, oxo, hydroxyl, OCF3 and CF3 radicals.
17. A pharmaceutical composition according to claim 13 comprising, as an active ingredient, at least one compound of formula (I) wherein • Ri represents a radical --N(Rs)--Y--R6, • Y is S02, • R2 represents either a phenyl which is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, trifluoromethyl, trifluoromethoxy or hydroxyalkyl radicals; or a heteroaromatic radical selected from pyridyl and pyrimidyl rings, it being possible for these heteroaromatic radicals to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl or trifluoromethoxy radical, • R3 represents either a phenyl which is unsubstituted or substituted with one or more halogen atoms or alkyl, alkoxy, trifluoromethyl, trifluoromethoxy or hydroxyalkyl radicals; or a heteroaromatic 74 151209/2 radical selected from pyridyl and pyrimidyl rings, it being possible for these heteroaromatic radicals to be unsubstituted or substituted with a halogen atom or an alkyl, alkoxy, hydroxyl, trifluoromethyl or trifluoromethoxy radical, • R5 represents a hydrogen atom or an alkyl radical, • B.6 represents a naphthyl, phenylalkyl, Het or phenyl radical optionally substituted with one or more halogen atoms or alkyl, alkoxy, -NR14 R15, hydroxyl, hydroxyalkyl, OCF3, CF3 or -SO2 NH2 radicals, or alternatively, a fused ring containing a 3-10 membered Het radical is formed on 2 adjacent carbon atoms of said phenyl radical, with dioxymethylene, • Ri4 and which are identical or different, represent a hydrogen atom or an alkyl, cycloalkyl, alkylcycloalkyl or hydroxyalkyl radical or alternatively R14 and Ri5 together with the nitrogen atom to which they are attached form a 3- to 10-membered saturated or unsaturated mono- or bicyclic heterocycle, optionally containing another heteroatom selected from oxygen, sulfur and nitrogen and being optionally substituted with one or more alkyl, oxo, hydroxyalkyl or -CO-NH2 radicals, • Het represents a 3- to 10-membered unsaturated or saturated mono- or bicyclic heterocycle containing one or more heteroatoms selected from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, alkoxycarbonyl, oxo or hydroxyl radicals, the nitrogen-containing heterocycles being optionally in their N-oxidized form, an optical isomer of such a compound or one of its pharmaceutically acceptable salts.
18. A pharmaceutical composition according to claim 17 wherein, in the compound of formula (I), Het represents a heterocycle selected from benzimidazole, benzoxazole, benzothiazole, benzothiophene, thiophene, 75 151209/2 quinoline, pyrrole, pyridine, pyrimidine, thiazole, thiadiazole, furan, tetrahydroisoquinoline and tetrahydroquinoline, these heterocycles being optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, oxo, hydroxyl, OCF3 or CF3 radicals. #580878
IL151209A 2000-03-03 2002-08-12 Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation IL151209A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0002777A FR2805810B1 (en) 2000-03-03 2000-03-03 PHARMACEUTICAL COMPOSITIONS CONTAINING 3- AMINO-AZETIDINE DERIVATIVES, THE NEW DERIVATIVES AND THEIR PREPARATION
PCT/FR2001/000601 WO2001064633A1 (en) 2000-03-03 2001-03-01 Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof

Publications (1)

Publication Number Publication Date
IL151209A true IL151209A (en) 2010-05-17

Family

ID=8847707

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15120901A IL151209A0 (en) 2000-03-03 2001-03-01 Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
IL151209A IL151209A (en) 2000-03-03 2002-08-12 Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL15120901A IL151209A0 (en) 2000-03-03 2001-03-01 Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation

Country Status (35)

Country Link
EP (1) EP1263721B1 (en)
JP (1) JP2003525269A (en)
KR (1) KR100813740B1 (en)
CN (1) CN1187325C (en)
AR (1) AR034405A1 (en)
AT (1) ATE478840T1 (en)
AU (2) AU3752601A (en)
BG (1) BG107057A (en)
BR (1) BR0108894A (en)
CA (1) CA2400138A1 (en)
CY (1) CY1111075T1 (en)
DE (1) DE60142890D1 (en)
DK (1) DK1263721T3 (en)
DZ (1) DZ3311A1 (en)
EA (1) EA004649B1 (en)
EE (1) EE05081B1 (en)
ES (1) ES2351183T3 (en)
FR (1) FR2805810B1 (en)
HR (1) HRP20020710A2 (en)
HU (1) HUP0300350A2 (en)
IL (2) IL151209A0 (en)
MA (1) MA26879A1 (en)
MX (1) MXPA02008346A (en)
NO (1) NO324523B1 (en)
NZ (1) NZ521076A (en)
OA (1) OA12221A (en)
PL (1) PL365007A1 (en)
PT (1) PT1263721E (en)
SI (1) SI1263721T1 (en)
SK (1) SK12442002A3 (en)
TW (1) TWI294420B (en)
UA (1) UA72319C2 (en)
WO (1) WO2001064633A1 (en)
YU (1) YU65902A (en)
ZA (1) ZA200206916B (en)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022579A2 (en) 2000-09-11 2002-03-21 Sepracor, Inc. Antipsychotic sulfonamide-heterocycles, and methods of use thereof
FR2814678B1 (en) * 2000-10-04 2002-12-20 Aventis Pharma Sa COMBINATION OF AN ANTAGONIST OF THE CB1 RECEPTOR AND SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF OBESITY
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
FR2833842B1 (en) * 2001-12-21 2004-02-13 Aventis Pharma Sa PHARMACEUTICAL COMPOSITIONS BASED ON AZETIDINE DERIVATIVES
US7351729B2 (en) 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
JP3813152B2 (en) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド Substituted amides
FR2837706A1 (en) * 2002-03-28 2003-10-03 Sanofi Synthelabo USE OF A CB1 CANNABINOID RECEPTOR ANTAGONIST FOR THE PREPARATION OF MEDICINES USEFUL FOR THE TREATMENT OF SEXUAL DYSFUNCTION AND / OR IMPROVING SEXUAL PERFORMANCE
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
BR0313041A (en) 2002-07-29 2005-06-21 Hoffmann La Roche Compounds; pharmaceutical compositions; method for the treatment and / or prophylaxis of diseases that are associated with cb1 receptor modulation; and use of compounds
BR0317931A (en) 2003-01-02 2005-11-29 Hoffmann La Roche Compounds, process for manufacturing them, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases that are associated with cb1 receptor modulation and use of the compounds
JP4444120B2 (en) 2003-01-02 2010-03-31 エフ．ホフマン−ラ ロシュ アーゲー Novel CB1 receptor inverse agonist
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE398449T1 (en) * 2003-05-01 2008-07-15 Vernalis Res Ltd USE OF AZETIDINE CARBOXAMIDE DERIVATIVES IN THERAPY
EP1636181A1 (en) * 2003-06-11 2006-03-22 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
KR100809201B1 (en) 2003-06-20 2008-02-29 에프. 호프만-라 로슈 아게 2-aminobenzothiazoles as cb1 receptor inverse agonists
AU2004274309B2 (en) 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
AU2004299198A1 (en) 2003-12-08 2005-06-30 F. Hoffmann-La Roche Ag Novel thiazole derivates
CA2553970A1 (en) 2004-01-28 2005-08-18 F. Hoffmann-La Roche Ag Spiro-benzodioxoles and their use as cb1 antagonists
KR20060124756A (en) * 2004-02-17 2006-12-05 라보라토리오스 델 드라. 에스테브.에스.에이. Substituted azetidine compounds, their preparation and use as medicaments
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc Method of treating men with metabolic and anthropometric disorders
CA2564986A1 (en) 2004-05-10 2005-11-17 F. Hoffmann-La Roche Ag Pyrrole or imidazole amides for treating obesity
EP1807398B1 (en) 2004-10-27 2008-06-25 F. Hoffmann-Roche AG New indole or benzimidazole derivatives
CA2586068A1 (en) 2004-11-09 2006-05-18 F.Hoffmann-La Roche Ag Dibenzosuberone derivatives
CA2602787C (en) 2005-04-06 2013-12-24 F. Hoffmann-La Roche Ag Pyridine-3-carboxamide derivatives as cb1 inverse agonists
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
JP2008545739A (en) 2005-06-02 2008-12-18 グレンマーク・ファーマシューティカルズ・エスエー Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and methods for their preparation
JPWO2007018248A1 (en) 2005-08-10 2009-02-19 萬有製薬株式会社 Pyridone compounds
KR101440409B1 (en) 2005-08-18 2014-09-15 닛산 가가쿠 고교 가부시키 가이샤 Thiophene compound having sulfonyl group and process for producing the same
JPWO2007024004A1 (en) 2005-08-24 2009-03-05 萬有製薬株式会社 Phenylpyridone derivatives
CA2621470A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JPWO2007049798A1 (en) 2005-10-27 2009-04-30 萬有製薬株式会社 New benzooxathiin derivatives
NZ568292A (en) 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
AR058199A1 (en) * 2005-11-28 2008-01-23 Merck & Co Inc DERIVATIVES OF 3- RENTED ALQUILAZETIDINA WITH HETEROCICLOS
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
RU2009108280A (en) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Arylamino-arylalkyl-substituted imidazolidine-2,4-dione, methods for their preparation containing these compounds and their use
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
JP5489333B2 (en) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション Methods of treatment using fatty acid synthesis inhibitors
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (en) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
JPWO2009119726A1 (en) 2008-03-28 2011-07-28 Ｍｓｄ株式会社 Diarylmethylamide derivatives having melanin-concentrating hormone receptor antagonistic activity
JP2011522828A (en) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
CA2727914A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diaryl ketoxime derivative technical field
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (en) 2008-07-30 2010-02-04 萬有製薬株式会社 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
JP5514831B2 (en) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション Substituted bicyclic amines for the treatment of diabetes
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2011137024A1 (en) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
EP2579873A4 (en) 2010-06-11 2013-11-27 Merck Sharp & Dohme Novel prolylcarboxypeptidase inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
JP2013540160A (en) * 2010-10-22 2013-10-31 ヤンセン ファーマシューティカ エヌ．ベー． Amino-pyrrolidine-azetidine diamide as monoacylglycerol lipase inhibitor
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
CN105001219A (en) 2011-02-25 2015-10-28 默沙东公司 Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
EP2683703B1 (en) 2011-03-08 2015-05-27 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683698B1 (en) 2011-03-08 2017-10-04 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
KR20150036245A (en) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 Antidiabetic tricyclic compounds
BR112015019836A2 (en) 2013-02-22 2017-07-18 Merck Sharp & Dohme compound, pharmaceutical composition, and use of a compound
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EA201592263A1 (en) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. ULTRASCULAR AGONISTS OF GUANYLACYCLASE C, METHOD OF THEIR RECEIVING AND USING
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2017002610A (en) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBITORS OF A-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE.
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3883930A1 (en) 2018-11-20 2021-09-29 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
TW202045476A (en) 2019-02-13 2020-12-16 美商默沙東藥廠 5-alkyl pyrrolidine orexin receptor agonists
US20230018413A1 (en) 2019-08-08 2023-01-19 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
KR20230053639A (en) 2020-08-18 2023-04-21 머크 샤프 앤드 돔 엘엘씨 Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4242261A (en) * 1979-07-19 1980-12-30 A. H. Robins Company, Inc. Production of methylene-cycloamines
FR2649100B1 (en) * 1989-06-29 1994-03-04 Laboratorios Dr Esteve Sa NOVEL AZETIDINES, THEIR PREPARATION AND THEIR APPLICATION AS INTERMEDIATES FOR THE PREPARATION OF COMPOUNDS WITH ANTIMICROBIAL ACTIVITY
JPH05201971A (en) * 1992-01-28 1993-08-10 Hokuriku Seiyaku Co Ltd Benzenesulfonamide derivative containing cyclic amine
US6022868A (en) * 1995-06-29 2000-02-08 Novo Nordisk Als Substituted azacyclic or azabicyclic compounds
GB9714129D0 (en) * 1997-07-04 1997-09-10 Pfizer Ltd Azetidines

Also Published As

Publication number Publication date
ZA200206916B (en) 2003-07-17
CY1111075T1 (en) 2015-06-11
EP1263721A1 (en) 2002-12-11
BG107057A (en) 2003-07-31
ATE478840T1 (en) 2010-09-15
PT1263721E (en) 2010-10-28
FR2805810B1 (en) 2002-04-26
CN1411440A (en) 2003-04-16
NO20024176D0 (en) 2002-09-02
EE200200486A (en) 2004-02-16
KR100813740B1 (en) 2008-03-13
ES2351183T3 (en) 2011-02-01
TWI294420B (en) 2008-03-11
YU65902A (en) 2005-09-19
UA72319C2 (en) 2005-02-15
IL151209A0 (en) 2003-04-10
AR034405A1 (en) 2004-02-25
EE05081B1 (en) 2008-10-15
NZ521076A (en) 2004-08-27
FR2805810A1 (en) 2001-09-07
JP2003525269A (en) 2003-08-26
CN1187325C (en) 2005-02-02
CA2400138A1 (en) 2001-09-07
SK12442002A3 (en) 2003-02-04
OA12221A (en) 2006-05-10
DK1263721T3 (en) 2011-01-03
HUP0300350A2 (en) 2003-06-28
PL365007A1 (en) 2004-12-27
HRP20020710A2 (en) 2005-06-30
AU3752601A (en) 2001-09-12
NO20024176L (en) 2002-10-29
MXPA02008346A (en) 2002-12-13
BR0108894A (en) 2003-04-29
EA200200942A1 (en) 2003-02-27
NO324523B1 (en) 2007-11-12
EP1263721B1 (en) 2010-08-25
AU2001237526B2 (en) 2006-01-05
MA26879A1 (en) 2004-12-20
DE60142890D1 (en) 2010-10-07
EA004649B1 (en) 2004-06-24
KR20030013375A (en) 2003-02-14
WO2001064633A1 (en) 2001-09-07
SI1263721T1 (en) 2011-01-31
DZ3311A1 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
US6566356B2 (en) Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
AU2001237526B2 (en) Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
US6355631B1 (en) Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
AU780880B2 (en) Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof
KR100786411B1 (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
IL141769A (en) Azetidine derivatives, their preparation and medicines containing them

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees